WO2005089861A1 - Modular stimulation lead network - Google Patents

Modular stimulation lead network Download PDF

Info

Publication number
WO2005089861A1
WO2005089861A1 PCT/US2005/007179 US2005007179W WO2005089861A1 WO 2005089861 A1 WO2005089861 A1 WO 2005089861A1 US 2005007179 W US2005007179 W US 2005007179W WO 2005089861 A1 WO2005089861 A1 WO 2005089861A1
Authority
WO
WIPO (PCT)
Prior art keywords
stimulation
elongated body
kit
coupling mechanism
lead
Prior art date
Application number
PCT/US2005/007179
Other languages
French (fr)
Inventor
Robert J. Garabedian
Michael P. Wallace
Original Assignee
Boston Scientific Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Scientific Limited filed Critical Boston Scientific Limited
Priority to AT05724681T priority Critical patent/ATE510580T1/en
Priority to JP2007502876A priority patent/JP4635045B2/en
Priority to EP05724681A priority patent/EP1722846B1/en
Priority to CA002557743A priority patent/CA2557743A1/en
Publication of WO2005089861A1 publication Critical patent/WO2005089861A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36071Pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36017External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36021External stimulators, e.g. with patch electrodes for treatment of pain

Definitions

  • the invention relates to the implantation of electrode leads within a patient's spine to treat disorders, such as chronic pain.
  • a percutaneous lead comprises a cylindrical body with ring electrodes, and can be introduced into contact with the affected spinal tissue through a Touhy-like needle, which passes through the skin, between the desired vertebrae, and into the spinal cavity above the dura layer.
  • a percutaneous lead is placed on the corresponding lateral side of the spinal cord.
  • a percutaneous lead is placed down the midline of the spinal cord, or two percutaneous leads are placed down the respective sides of the midline.
  • a surgical lead has a paddle on which multiple electrodes are arranged in independent columns, and is introduced into contact with the affected spinal tissue using a surgical procedure, and specifically, a laminectomy, which involves removal of the laminar vertebral tissue to allow both access to the dura layer and positioning of the lead.
  • the lead(s) are anchored in place, and the proximal ends of the lead(s), or alternatively lead extensions, are passed through a tunnel leading to a subcutaneous pocket (typically made in the patient's abdominal area) where a neurostimulator is implanted.
  • the lead(s) are connected to the neurostimulator, which is then operated to test the effect of stimulation and adjust the parameters of the stimulation for optimal pain relief.
  • the patient provides verbal feedback regarding the presence of paresthesia over the pain area. Based on this feedback, the lead position(s) may be adjusted and re-anchored if necessary.
  • a stimulation kit comprising first and second tissue stimulation leads.
  • the first stimulation lead comprises a first elongated body, a first stimulation element (e.g., an electrode), and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body.
  • the second stimulation lead comprises a second elongated body, a second stimulation element (e.g., an electrode), and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism, e.g., in a rail and slot arrangement.
  • the stimulation kit may optionally comprise a stimulation source configured to be coupled to the first and second stimulation leads.
  • each of the stimulation leads comprises a plurality of stimulation elements in order to provide a more extensive stimulation coverage.
  • the first and second elongated bodies may be cylindrically-shaped, although other shapes are possible depending on the particular application. The size of the elongated bodies can be any size that is consistent with the stimulation procedure in which the stimulation leads will be employed.
  • the greatest cross-sectional dimension of at least one of the elongated bodies is preferably 5 mm or less in order to minimize the size of the opening through which the stimulation leads will be introduced.
  • the elongated bodies can have the same length, or alternatively, one elongated body can be shorter than the other, such that, e.g., the shorter elongated body can be entirely delivered within the patient's body without any portion extending from the access opening.
  • the stimulation elements of the respective stimulation leads face the same direction, e.g., to focus the stimulation energy in one direction.
  • the stimulation elements may be mounted directly on the elongated bodies, or alternatively, may be mounted to some other element of the stimulation leads.
  • the second stimulation lead may have a flap on which the respective stimulation element is disposed.
  • the flap may extend along a portion of the complementary coupling mechanism, so that it can be secured by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably engages the coupling mechanism of the first stimulation lead and released by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably disengages the coupling mechanism of the first stimulation lead.
  • the distal end of the second elongated body may be configured to be in close contact with the first elongated body when engaging each other.
  • the first elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementation coupling mechanism from the coupling mechanism of the first stimulation lead.
  • the distal end of the second elongated body can be pre-curved to provide it with a predefined configuration.
  • the second elongated body may be configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body.
  • the kit may comprise a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry.
  • the secondary stimulation lead may comprise a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry.
  • the kit may have more than two stimulation leads.
  • the first stimulation lead may comprise another coupling mechanism longitudinally extending along at least a portion of the respective elongated body, in which case, the kit may further comprise a third stimulation lead comprising an elongated body, a stimulation element mounted on the elongated body, and another complementary coupling mechanism configured to slidably engage the other coupling mechanism of the first stimulation lead.
  • the stimulation kit is similar to the previously described stimulation kit, with the exception that it comprises a guide and a stimulation lead.
  • the guide is similar to the first stimulation lead of the previously described stimulation kit, with the exception that it need not have a stimulation element.
  • a medical kit is similar to the previously described stimulation kit, with the exception that the medical kit comprises first and second medical leads with respective operative elements that are not limited to stimulation elements, but rather can be any elements that are capable of performing a medical function within a targeted tissue region.
  • the medical kit comprises a guide and a medical lead. The guide is similar to the first medical lead of the previously described medical kit, with the exception that it need not have an operative element.
  • Fig. 1 is a plan view of a modular stimulation lead kit arranged in accordance with one embodiment of the invention
  • Fig. 2 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 1
  • Fig. 3 is a cutaway perspective view of a primary stimulation lead used in the kit of Fig. 1
  • Fig. 4 is a cutaway perspective view of a secondary stimulation lead used in the kit of Fig. 1
  • Fig. 5 is a cross-sectional view of the stimulation lead assembly of Fig. 2, taken along the line 5-5;
  • Fig. 1 is a plan view of a modular stimulation lead kit arranged in accordance with one embodiment of the invention
  • Fig. 2 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 1
  • Fig. 3 is a cutaway perspective view of a primary stimulation lead used in the kit of Fig. 1
  • Fig. 4 is a cutaway perspective view of a secondary stimulation lead used in the kit of Fig
  • FIG. 6 is a cutaway view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 ;
  • Fig. 7 is a cross-sectional view of the stimulation lead assembly of Fig. 6, taken along the line 7-7;
  • Figs. 8A-8D are various views illustrating the installation of the kit of Fig. 1 into a patient's spine;
  • Fig. 9 is a plan view of another modular stimulation lead kit arranged in accordance with another embodiment of the invention;
  • Fig. 10 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 9;
  • Fig. 11 is a cross-sectional view of the secondary stimulation lead of Fig. 10, taken along the line 11-11 ;
  • FIGS. 12A-12B are various views illustrating the installation of the kit of Fig. 9 into a patient's spine;
  • FIG. 13 is a partially cutaway top view of the distal end of an alternative primary stimulation lead that can be used in kit of Fig. 1 ;
  • Fig. 14a is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads are shown in a normally curved geometry that converges towards the primary stimulation lead;
  • Fig. 15a is a cross-sectional view of the stimulation lead assembly of Fig. 14a, taken along the line 15a-15a;
  • FIG. 14b is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a stylet is introduced;
  • Fig. 15b is a cross-sectional view of the stimulation lead assembly of Fig. 14b, taken along the line 15b-15b;
  • Fig. 14c is a cutaway top view of another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a pullwire is tensioned;
  • Fig. 15b is a cross-sectional view of the stimulation lead assembly of Fig. 14b, taken along the line 15b-15b
  • Fig. 14c is a cutaway top view of another alternative stimulation lead assembly that can be formed from the kit of Fig
  • FIG. 15c is a cross-sectional view of the stimulation lead assembly of Fig. 14c, taken along the line 15c-15c;
  • Fig. 14d is a cutaway top view of still another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 3 is used, wherein the secondary stimulation leads can be placed into a curved geometry that bows away from the primary stimulation lead;
  • Fig. 15d is a cross-sectional view of the stimulation lead assembly of Fig. 14d, taken along the line 15d-15d;
  • Fig. 15e is a cross-sectional view of the stimulation lead assembly of Fig. 14d, taken along the line 15e-15e;
  • Fig. 15f is a cross-sectional view of the stimulation lead assembly of Fig.
  • Fig. 16 is a cutaway top view of an alternative stimulation lead assembly
  • Fig. 17 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing an electrode flap of a secondary stimulation lead constrained by the primary stimulation lead
  • Fig. 18 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing the electrode flap of the secondary stimulation lead released by the primary stimulation lead.
  • a modular stimulation lead kit 100 arranged in accordance with one embodiment of the invention, generally comprises a primary stimulation lead 102 and two secondary stimulation leads 104, which are configured to be percutaneously delivered and implanted into the epidural space of a patient's spine, an implantable electrical stimulation source 106 configured for delivering stimulation energy to the stimulation leads 102/104, and an optional extension lead 108 configured for connecting the stimulation leads 102/104 to the remotely implanted stimulation source 106.
  • the secondary stimulation leads 104 can be attached to the primary stimulation lead 102 to form a modularized stimulation lead assembly 110, as illustrated in Fig. 2.
  • kits 100 illustrated in Fig. 1 are described herein as being used in spinal cord stimulation (SCS) for the treatment of chronic pain
  • the kit 100 or a modification of the kit 100
  • the stimulation leads 102/104 can be delivered through a miniature cranial burr hole into the brain tissue.
  • the primary stimulation lead 102 comprises an elongated sheath body 112 having a proximal end 114 and a distal end 116.
  • the sheath body 112 is composed of a suitably flexible material (such as polyurethane, silicone, etc.), which may either be resilient or non-resilient, and may be formed via an extrusion process or by any other suitable means.
  • the distal end 116 of the sheath body 112 is soft and tapered to prevent injury to nerve roots that exit the spinal cord when delivered into the epidural space of the patient's spine.
  • the sheath body 112 is cylindrically-shaped and sized to fit through a Touhy-like needle (not shown). In this case, the diameter of the sheath body 112 is preferably less than 5 mm to allow it to be percutaneously introduced through a needle.
  • the diameter of the sheath body 112 is within the range of 1 mm to 3 mm, so that the primary stimulation lead 102, along with the secondary stimulation leads 104 described below, can comfortably fit within the epidural space of the patient.
  • the sheath body 112 may have other cross-sectional geometries, such as elliptical, rectangular, triangular, etc. If rectangular, the width of the primary stimulation lead 102 can be up to 5 mm, since the width of an epidural space is greater than its height.
  • the sheath body 112 may have an optional lumen (not shown) for receiving a stylet (not shown) that axially stiffens the sheath body 112 to facilitate percutaneous introduction of the primary stimulation lead 102 within the epidural space of the patient's spine, as will be described in further detail below.
  • the primary stimulation lead 102 further comprises a plurality of terminals 118 (in this case, three) mounted on the proximal end 114 of the sheath body 112, and a plurality of stimulation elements, and in particular electrodes 120 (in this case, three), mounted on the distal end 116 of the sheath body 112.
  • the terminals 118 are formed of ring-shaped elements composed of a suitable biocompatible metallic material, such as platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials, and can be mounted to the sheath body 112 in an interference fit arrangement.
  • the electrodes 120 are formed on one circumferential side of the sheath body 112 (shown best in Fig. 3) in order to focus stimulation energy in one direction, thereby maximizing energy efficiency.
  • the electrodes 120 can be formed onto the sheath body 112 using known deposition processes, such as sputtering, vapor deposition, ion beam deposition, electroplating over a deposited seed layer, or a combination of these processes.
  • the electrodes 120 can be formed onto the sheath body 112 as a thin sheet or foil of electrically conductive metal affixed to the wall of the sheath body 112.
  • the electrodes 120 can be composed of the same electrically conductive and biocompatible material as the terminals 118, e.g., platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials.
  • the primary stimulation lead 102 further comprises a plurality of conductors
  • the conductors 122 are composed of a suitably electrically conductive material that exhibits the desired mechanical properties of low resistance, corrosion resistance, flexibility, and strength.
  • each secondary stimulation lead 104 comprises an elongated sheath body 132 having a proximal end 134 and a distal end 136, a plurality of terminals 138 (in this case, four) mounted to the proximal end 134 of the sheath body 132, a plurality of electrodes 140 (in this case, four) mounted to the distal end 136 of the sheath body 132, and a plurality of conductors 142 (shown in Fig. 4) extending through the sheath body 132 and respectively connecting the electrodes 120 to the terminals 118.
  • the sheath bodies 132 of the secondary stimulation leads 104 are similar to the sheath body 112 of the primary stimulation lead 102, with the exception that the distal ends 136 are tapered in only one direction. In this manner, the stimulation lead assembly 110, as illustrated in Fig. 2, forms a lower profile distal end to facilitate placement of the assembly 110 within the epidural space of the patient's spine.
  • the sheath bodies 132 of the secondary stimulation leads 104 may each have an optional lumen (not shown) for receiving a stylet (not shown) to facilitate percutaneous introduction of the secondary stimulation lead 104 within the epidural space of the patient's spine, as will be described in further detail below.
  • the terminals 118 and electrodes 120 of the secondary stimulation leads 104 are similar to the terminals 118 and electrodes 120 of the primary stimulation lead 102, with the exception that there are four sets of terminals 118 and electrodes 120 instead of three.
  • the electrodes 120 of the secondary stimulation leads 104 face the same direction as the electrodes 140 of the primary stimulation leads 102, so that the entire stimulation lead assembly 110 is capable of focusing electrical energy in a single direction, as shown in Fig. 3. Also, as illustrated in Fig.
  • the electrodes 120/140 are arranged on the respective sheath bodies 112/132, such that the electrodes 140 of the secondary stimulation leads 104 are offset from the electrodes 120 of the primary stimulation lead 102 in the longitudinal direction, thereby preventing accidental shorting between adjacent electrodes when the assembly 110 is formed. Further details regarding the structure and composition of standard percutaneous stimulation leads are disclosed in U.S. Patent No. 6,216,045.
  • the primary stimulation lead 102 and the respective secondary stimulation leads 104 are configured to slidably engage each other to form the lead assembly 110 illustrated in Fig. 2.
  • the primary stimulation lead 102 comprises a pair of circumferentially opposed slots 150 extending along the length of the sheath body 112.
  • the slots 150 can be formed in the sheath body 112 using any one of a variety of manners, but in the illustrated embodiment, the slots 150 are formed during the extrusion process. Alternatively, the slots 150 can be formed by embedding, or otherwise mounting, discrete slotted members (not shown) along the sheath body 112.
  • each of the secondary stimulation leads 104 comprises a rail 152 extending along the sheath body 132.
  • the rail 152 can be formed on the sheath body 132 using any one of a variety of manners, such as forming the rail 152 during the extrusion process. Alternatively, the rail 152 can be formed of a discrete member (not shown) that is bonded, or otherwise mounted, to the sheath body 132.
  • the primary stimulation lead 102 may have a pair of circumferentially opposed rails extending along its sheath body 112, while the secondary stimulation leads 104 may have slots 150 extending along their sheath bodies 132.
  • the rails 152 and slots 150 are sized to snuggly engage each other in a sliding relationship, as best shown in Fig. 5.
  • the secondary stimulation leads 104 can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming the stimulation assembly 110 illustrated in Fig. 2.
  • the opposing slots 150 of the primary stimulation lead 102 and the rails 152 of the secondary stimulation leads 104 are circumferentially offset ninety degrees from the centers of the respective electrodes 120. In this manner, all of the electrodes 120, which generally face in the same direction, as described above, are ensured to face in a direction perpendicular to the plane of the assembly 110, thereby maximizing transmission of the stimulation energy into the target neural tissue when the assembly 110 is fully implanted within the epidural space of the patient's spine.
  • a rail and slot arrangement has been disclosed as the preferred means of slidably engaging the primary and stimulation leads 102/104, other means of slidably engaging the leads can be provided.
  • the primary stimulation lead can have loop structures (not shown) that extend along the opposing sides the respective sheath body.
  • the secondary stimulation leads 104 can then be introduced through the respective sets of loop structures in order to couple the leads together.
  • the slots 150 have distal rail stops (not shown), i.e., the distal ends of the slots 150 terminate prior to the distal tip of the sheath body 112 to prevent the distal ends 136 of the secondary stimulation leads 104 from sliding distal to the distal end 116 of the primary stimulation lead 102.
  • the distal ends of the slots 150 may have chamfered openings 151 , as illustrated in Fig. 13.
  • the distal ends of the secondary stimulation leads 104 will diverge from the distal end of the primary stimulation lead 102 when the leads 102/104 are slidably engaged with each other. That is, when the rail 152 of a secondary stimulation lead 104 is slid along the respective slot 150 of the primary stimulation lead 102, the distal end of the rail 152 will be diverted out of the chamfered opening 151 at the distal end of the slot 150, thereby expanding the footprint of the resulting assembly 110, as illustrated in Fig. 14a.
  • the secondary stimulation lead 104 may have a proximal rail stop (not shown) to prevent further sliding of the respective secondary stimulation lead 104 when fully deployed.
  • the distal ends of the secondary stimulation leads 104 can be pre-curved inward towards the primary stimulation lead 102, as illustrated in Fig. 14a, so that the distal ends of the secondary stimulation leads 104, when deployed from the primary stimulation lead 102, extend in a parallel direction with the distal end of the primary stimulation lead 102.
  • the distal ends of the secondary stimulation leads 104 can be pre-curved in any one of a variety of manners.
  • a pre-curved resilient member 153 composed of a suitable material, such as nitinol, can be formed within the sheath body 132.
  • the cross-section of the resilient member 153 resembles of flat plate, so that the sheath body 132 consistently bends in a pre-defined plane, i.e., within the plane of the assembly 110.
  • the distal ends of the secondary stimulation leads 104 are not pre-curved, but rather normally exhibit a straight geometry after exiting slot 150 of the primary stimulation lead 102 (shown in phantom in Fig. 14b), such that the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102.
  • the distal ends of the secondary stimulation leads 104 may not be resilient.
  • the secondary stimulation lead 104 comprises a lumen 155 through which a curved stylet 157 is introduced, as illustrated in Fig. 15b.
  • the distal end of the stylet 157 is curved, such that, when introduced through the lumen 155, the distal end of the respective stimulation lead 104 assumes a geometry that curves inward towards the primary stimulation lead 102, as illustrated in Fig. 14b.
  • Differently curved stylets 157 can be used in order to provide the distal end of the secondary stimulation lead 104 with the desired curved geometry.
  • the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig.
  • the distal end of the stylet 157 can be straight, so that its introduction through the lumen 157 straightens the pre-curved distal end of the secondary stimulation lead 104, as shown in phantom in Fig. 14b.
  • a steering mechanism can be used to control the shape of the secondary stimulation lead 104.
  • the distal ends of the secondary stimulation leads 104 normally exhibit a straight geometry, in which case, the resilient member 153 is likewise formed into a straight geometry.
  • the secondary stimulation lead 104 comprises a pullwire lumen 159 and an associated pullwire 161 mounted to the inside surface of the distal end of the resilient member 153.
  • the distal end of the secondary stimulation lead 104 assumes the straight geometry. In this case, the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102, as illustrated in Fig. 14c. In contrast, when the pullwire 161 is pulled, the distal end of the secondary stimulation lead 104 assumes a geometry (shown in phantom) that curves inward towards the primary stimulation lead 102. Notably, the proximal-most portion of the distal ends of the secondary stimulation leads 104 does not contain the resilient member 153, so that the respective stimulation lead 104 bends at this portion when the pullwire 161 is pulled.
  • the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig. 14a.
  • the pullwire 161 can be mounted to the outside surface of the distal end of the resilient member 153, such that relaxation of the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a curved geometry that converges towards the primary stimulation lead 102, whereas the application of tension on the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a lesser curved or straight geometry that diverges from the primary stimulation lead 102.
  • a portion of the secondary stimulation lead 104 may not have a rail, so that it bows outward after the primary stimulation lead 102 and secondary stimulation lead 104 are fully engaged, as illustrated in Fig. 14d.
  • the rail 152 extends along the distal-most and proximal- most portions of the distal end of the second stimulation lead 104, but does not extend along a medial-portion of the distal end of the second stimulation lead 104.
  • the 14a-d are formed of three stimulation leads, less or more than three stimulation leads can be used.
  • the primary stimulation lead 102 may only have one slot 150 formed along one side of the respective body 112, or alternatively, if the primary stimulation lead 102 comprises two opposing slots 150, only one will be used to couple the lone secondary stimulation lead 104 thereto.
  • the secondary stimulation leads 104 may have a pair of circumferentially opposed rails 152.
  • two secondary stimulation leads 103 (which are similar to the secondary stimulation leads 104, but with a pair of circumferentially opposing rails 152) can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming a partial assembly similar to that illustrated in Fig. 3.
  • two additional secondary stimulation leads 105 (which are similar to secondary stimulation leads 105, but have a pair of circumferentially opposed slots 150) can be coupled to the secondary stimulation leads 105 by sliding the slots 150 of the additional secondary stimulation leads 102 along the respective rails 152, thereby forming a full assembly 160, as illustrated in Figs. 6 and 7.
  • the implantable stimulation source 106 is designed to deliver electrical pulses to the stimulation leads 102/104 in accordance with programmed parameters.
  • the stimulation source 106 is programmed to output electrical pulses having amplitudes varying from 0.1 to 20 volts, pulse widths varying from 0.02 to 1.5 milliseconds, and repetition rates varying from 2 to 2500 Hertz.
  • the stimulation source 106 takes the form of a totally self-contained generator, which once implanted, may be activated and controlled by an outside telemetry source, e.g., a small magnet.
  • the pulse generator has an internal power source that limits the life of the pulse generator to a few years, and after the power source is expended, the pulse generator must be replaced.
  • these types of stimulation sources 106 may be implanted within the chest or abdominal region beneath the skin of the patient.
  • the implantable stimulation source 106 may take the form of a passive receiver that receives radio frequency (RF) signals from an external transmitter worn by the patient.
  • RF radio frequency
  • the life of the stimulation source 106 is virtually unlimited, since the stimulation signals originate from the external transmitter.
  • the receivers of these types of stimulation sources 106 can be implanted within the chest or abdominal region beneath the skin of the patient.
  • the receivers may also be suitable for implantation behind the ear of the patient, in which case, the external transmitter may be worn on the ear of the patient in a manner similar to that of a hearing aid.
  • Stimulation sources such as those just described, are commercially available from Advanced Neuromodulation Systems, Inc., located in Piano, Texas, and Medtronic, Inc., located in Minneapolis, Minnesota.
  • the optional extension lead 108 comprises an elongated sheath body 144 having a proximal end 146 and a distal end 148, much like the sheath bodies
  • the extension lead 108 is sufficient to extend from the spine of the patient, where the proximal ends of the implanted stimulation leads 102/104 protrude from to the implantation site of the stimulation source 106 — typically somewhere in the chest or abdominal region.
  • the distal adapter 154 is configured to receive the proximal ends of the stimulation leads 102/104, and the proximal connector 156 is configured to couple to the stimulation source 106.
  • a needle 10 such as, e.g., a Touhy needle, is inserted through the patient's skin 12 between the desired vertebrae 14, and into the epidural space 16 within the spine at a position inferior to target stimulation site 18 (Fig. 8A).
  • the Touhy needle 10 will serve as the primary delivery mechanism for the primary stimulation lead 102.
  • a guide wire (not shown) is introduced through the needle 10 and advanced to or near the target stimulation site 18. The needle 10 is removed, the introducer is then introduced over the guide wire and advanced to the target stimulation site 18, and the guide wire is then withdrawn.
  • the introducer will serve as the primary delivery mechanism for the primary stimulation lead 102. After the deliver mechanism is in place, the primary stimulation lead 102 is then inserted through the needle or the introducer (whichever is in place), and positioned in the epidural space at the target stimulation site 18, with the electrodes 120 facing the dural layer 20 surrounding the spinal cord 22 (Fig. 8B).
  • a stylet can be used to provide additional axial stiffness and to facilitate control.
  • the needle 10 or introducer is removed, and one of the secondary stimulation leads 104 is delivered through the percutaneous opening 24 left by the removal of the needle 10, and into the epidural space 16 by slidably engaging the secondary stimulation lead 104 along the primary stimulation lead 102 (Fig. 8C).
  • the rail 152 of the secondary stimulation lead 104 is inserted into the corresponding slot 150 of the primary stimulation lead 102, and the secondary stimulation lead 104 is pushed until the distal end of the rail 152 abuts the distal end of the slot 150, thereby signifying that the secondary stimulation lead 104 is fully engaged with the primary stimulation lead 102 (with the electrodes 120/140 of the stimulation leads 102/104 adjacent, but offset from, each other) and is in its proper location within the epidural space 16 of the patient.
  • the other secondary stimulation lead 104 is then delivered into the epidural space by slidably engaging it along the primary stimulation lead 102 in the same manner, thereby completing the stimulation lead assembly 110 (Fig. 8D).
  • the secondary stimulation leads 104 have stylet lumens, a stylet can be used to provide additional axial stiffness and to facilitate control.
  • the electrodes 120/140 will span the midline of the spinal cord 22, much like the electrodes of a standard surgical lead do.
  • the proximal ends of the stimulation leads 102/104 are connected to a tester (not shown), which is then operated in a standard manner to confirm proper location of the stimulation lead assembly 110 and to adjust the stimulation parameters for optimal pain relief. Once this optimization process has been completed, the tester is disconnected from the stimulation leads 102/104, which are then anchored in place using standard lead anchors (not shown).
  • the stimulation lead assembly 110 is coupled to the stimulation source 106 and implantation is completed (not shown).
  • a subcutaneous pocket is created in the patient's abdominal area for implantation of the stimulation source 106, and a tunnel is subcutaneously formed between the spine region and the subcutaneous pocket.
  • the optional lead extension 108 is passed through the tunnel, after which the adapter 154 of the extension 108 is connected to the proximal ends of the stimulation leads 102/104 and the connector 156 of the lead extension 108 is connected to the stimulation source 106.
  • the stimulation source 106 is programmed and tested, and then placed within the subcutaneous pocket, after which all incisions are closed to effect implantation of the stimulation lead assembly 110 and stimulation source 106.
  • the stimulation source 106 can then be operated to convey stimulation energy from the stimulation source 106 to the electrodes 120/140 of the stimulation lead assembly 110, where it is, in turn, conveyed into the neural tissue for pain relief.
  • the stimulation lead assembly 110 can be subsequently retrieved from the patient's spine by removing the assembly 110 at the same time or by removing the assembly one stimulation lead 102/104 at a time by slidably disengaging the stimulation leads 102/104.
  • the rail and slot arrangement will pull the deployed distal end of the secondary stimulation leads 104 along side of the primary stimulation lead 102 when retrieved.
  • the relatively large footprint made by the stimulation lead assembly 110 provides a more stable platform for the electrodes 120/140.
  • the electrodes 120/140 face in a single direction, thereby focusing the stimulation energy into the affected neural tissue where it is needed.
  • the stimulation lead assembly 110 can be percutaneously delivered into the patient's spine in a minimally invasive and relatively pain-free manner, without requiring extensive patient recovery.
  • Fig. 9 a modular stimulation lead kit 200 arranged in accordance with another embodiment of the invention is shown.
  • each secondary stimulation lead 204 comprises a shortened sheath body 232, electrodes 240 mounted to the sheath body 232, electrical conductors 242 extending from the sheath body 232, and a connector 244 that receives the proximal ends of the electrical conductors 242.
  • the connector 244 comprises a plurality of terminals 238 that are similar to the previously described lead terminals 138.
  • the sheath body 232 is composed of the same material and has the same general shape as the sheath body 132 of the previously described secondary stimulation lead 104.
  • the sheath body 232 as illustrated in Fig. 9, however, is much shorter, so that it can be entirely received within the epidural space of the patient, i.e., the sheath body 232 will not extend out of the patient's back when fully deployed within the epidural space.
  • the electrical conductors 242, because they are exposed, are preferably composed of an electrically insulative material.
  • the kit 200 further comprises a pusher 214 that can be used to facilitate introduction of the respective secondary stimulation lead 204 along the primary stimulation lead 102 once the entire sheath body 232 of the secondary stimulation lead 204 is within the patient's back.
  • the pusher 214 comprises a cylindrical rod 216 having a distal tip 218 and a proximal end 220, and a handle 222 mounted on the proximal end 220 of the rod 216.
  • the distal tip 218 of the rod 216 is adapted to be received within an opening 224 (shown in Fig. 11) at the proximal end of the sheath body 232, thereby facilitating stable engagement between the pusher 214 and respective secondary stimulation lead 204.
  • the kit 200 can be installed and used in the same manner as the previously described kit 100 in treating chronic pain.
  • the patient is prepared and the primary stimulation lead 102 is delivered into the epidural space 16 of the patient's spine, so that the electrodes 120 are placed adjacent the target stimulation "site 18 in the same manner described above with respect to Fig. 8A and 8B.
  • One of the secondary stimulation leads 204 is then delivered into the epidural space 16 in the same manner as the secondary stimulation lead 104 described above was delivered, with the exception that the pusher 214 is used to advance the secondary stimulation lead 204 along the primary stimulation lead 102 until fully deployed within the epidural space 16 (Fig. 12A).
  • the remaining stimulation lead 204 is delivered into the epidural space 16 in the same manner to complete the stimulation lead assembly 210 (Fig. 12B).
  • the percutaneous opening 24 need only support, at most, two sheath bodies at one time, it can be made smaller, or alternatively, additional stimulation leads with shortened sheath bodies can be introduced within the epidural space 16 without increasing the size of the percutaneous opening.
  • the stimulation lead assembly 210 After the stimulation lead assembly 210 has been formed within the epidural space, it is tested and optimized.
  • the extension lead 108 is then connected between the stimulation leads 102/204 and the stimulation source 106, and the incisions are closed to fully implant the system, as previously described above.
  • a secondary stimulation lead 304 engaged with one side of the primary stimulation 102 is illustrated. Although not shown, another secondary stimulation lead 304 can be engaged with the opposite side of the primary stimulation lead 102.
  • the secondary stimulation lead 304 is similar to the previously described secondary stimulation lead 104, with the exception that the secondary stimulation lead 304 comprises a flap 303 on which the electrodes 140 are mounted.
  • the secondary stimulation lead 304 can, alternatively, have a shortened sheath body much like the secondary stimulation lead 204 illustrated in Fig. 9.
  • the flap 303 is designed to be constrained by the primary stimulation lead 102 to facilitate percutaneous delivery of the secondary stimulation lead 102, and released by the primary stimulation lead 102 to deploy the electrodes 140 into contact with the neural tissue.
  • the edge of the flap 303 comprises a coupling mechanism 305 that is designed to fit snugly within the respective slot 150 of the primary stimulation lead 102, along with the rail 152 of the secondary stimulation lead 102, when the secondary stimulation lead 304 is slidably engaged with the primary stimulation lead 102, as illustrated in Fig. 17.
  • the coupling mechanism 305 of the flap 303 will release from the slot 150, thereby allowing the flap 303 to deploy, placing the electrodes 140 into contact with the underlying tissue, as illustrated in Fig. 18.
  • the slots 150 in the primary stimulation lead 102 will not terminate as hereinbefore described, but will rather open up at the distal tip of the primary stimulation lead 102, so that the flap 303 can exit the respective slot 150 and be released by the primary stimulation lead 102.
  • Installation and use of the secondary stimulation lead 304 in forming the stimulation lead assembly 110 illustrated in Fig. 2, or alternatively the stimulation lead assembly 210 illustrated in Fig. 10, is similar that previously described above.
  • the primary stimulation lead 102 was used to provide a means of guiding the secondary stimulation leads 104 into the percutaneous opening within the patient and adjacent the target tissue region, as well as to provide a means of stimulating the tissue region
  • a guide member similar to the primary stimulation lead 102, but lacking stimulation capability, can be alternatively used to similarly guide the secondary stimulation leads 104 through the percutaneous opening to the target tissue region. In this case, only the secondary stimulation leads 104 will be used to stimulate tissue.

Abstract

A medical kit for treating an ailment, such as chronic pain, includes first and second medical leads, e.g., stimulation leads. Each lead comprises an elongated body and at least one operative element. The first medical lead comprises a coupling mechanism, such as a slot, and the second medical lead comprises a complementary mechanism, such as a rail, that slidably engages the coupling mechanism of the first medical lead.

Description

MODULAR STIMULATION LEAD NETWORK
FIELD OF THE INVENTION The invention relates to the implantation of electrode leads within a patient's spine to treat disorders, such as chronic pain.
BACKGROUND OF THE INVENTION It is known to treat chronic pain by electrically stimulating the spinal cord, spinal nerve roots, and other nerve bundles. In a typical procedure, one or more stimulation leads are introduced through the patient's back into the epidural space under fluoroscopy. Currently, there are two types of commercially available stimulation leads: a percutaneous lead and a surgical lead. A percutaneous lead comprises a cylindrical body with ring electrodes, and can be introduced into contact with the affected spinal tissue through a Touhy-like needle, which passes through the skin, between the desired vertebrae, and into the spinal cavity above the dura layer. For unilateral pain, a percutaneous lead is placed on the corresponding lateral side of the spinal cord. For bilateral pain, a percutaneous lead is placed down the midline of the spinal cord, or two percutaneous leads are placed down the respective sides of the midline. A surgical lead has a paddle on which multiple electrodes are arranged in independent columns, and is introduced into contact with the affected spinal tissue using a surgical procedure, and specifically, a laminectomy, which involves removal of the laminar vertebral tissue to allow both access to the dura layer and positioning of the lead. After the stimulation lead(s) (whether percutaneous or surgical) are placed at the target area of the spinal cord, the lead(s) are anchored in place, and the proximal ends of the lead(s), or alternatively lead extensions, are passed through a tunnel leading to a subcutaneous pocket (typically made in the patient's abdominal area) where a neurostimulator is implanted. The lead(s) are connected to the neurostimulator, which is then operated to test the effect of stimulation and adjust the parameters of the stimulation for optimal pain relief. During this procedure, the patient provides verbal feedback regarding the presence of paresthesia over the pain area. Based on this feedback, the lead position(s) may be adjusted and re-anchored if necessary. Although surgical leads have been functionally superior to percutaneous leads, there is one major drawback — surgical leads require painful surgery performed by a neurosurgeon, whereas percutaneous leads can be introduced into the epidural space minimally invasively by an anesthesiologist using local anesthesia. SUMMARY OF THE INVENTION In one embodiment of the invention, a stimulation kit comprising first and second tissue stimulation leads is provided. The first stimulation lead comprises a first elongated body, a first stimulation element (e.g., an electrode), and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body. The second stimulation lead comprises a second elongated body, a second stimulation element (e.g., an electrode), and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism, e.g., in a rail and slot arrangement. The stimulation kit may optionally comprise a stimulation source configured to be coupled to the first and second stimulation leads. Optionally, each of the stimulation leads comprises a plurality of stimulation elements in order to provide a more extensive stimulation coverage. The first and second elongated bodies may be cylindrically-shaped, although other shapes are possible depending on the particular application. The size of the elongated bodies can be any size that is consistent with the stimulation procedure in which the stimulation leads will be employed. Although, for medical procedures, such as spinal cord stimulation, the greatest cross-sectional dimension of at least one of the elongated bodies is preferably 5 mm or less in order to minimize the size of the opening through which the stimulation leads will be introduced. The elongated bodies can have the same length, or alternatively, one elongated body can be shorter than the other, such that, e.g., the shorter elongated body can be entirely delivered within the patient's body without any portion extending from the access opening. In one embodiment, the stimulation elements of the respective stimulation leads face the same direction, e.g., to focus the stimulation energy in one direction. The stimulation elements may be mounted directly on the elongated bodies, or alternatively, may be mounted to some other element of the stimulation leads. For example, the second stimulation lead may have a flap on which the respective stimulation element is disposed. In this case, the flap may extend along a portion of the complementary coupling mechanism, so that it can be secured by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably engages the coupling mechanism of the first stimulation lead and released by the coupling mechanism of the first stimulation lead when the portion of the complementary coupling mechanism slidably disengages the coupling mechanism of the first stimulation lead. The distal end of the second elongated body may be configured to be in close contact with the first elongated body when engaging each other. Alternatively, the first elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementation coupling mechanism from the coupling mechanism of the first stimulation lead. In this case, the distal end of the second elongated body can be pre-curved to provide it with a predefined configuration. Optionally, the second elongated body may be configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body. For example, the kit may comprise a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry. Or the secondary stimulation lead may comprise a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry. The kit may have more than two stimulation leads. For example, the first stimulation lead may comprise another coupling mechanism longitudinally extending along at least a portion of the respective elongated body, in which case, the kit may further comprise a third stimulation lead comprising an elongated body, a stimulation element mounted on the elongated body, and another complementary coupling mechanism configured to slidably engage the other coupling mechanism of the first stimulation lead. In one embodiment, the stimulation kit is similar to the previously described stimulation kit, with the exception that it comprises a guide and a stimulation lead. The guide is similar to the first stimulation lead of the previously described stimulation kit, with the exception that it need not have a stimulation element. In another embodiment, a medical kit is similar to the previously described stimulation kit, with the exception that the medical kit comprises first and second medical leads with respective operative elements that are not limited to stimulation elements, but rather can be any elements that are capable of performing a medical function within a targeted tissue region. In still another embodiment, the medical kit comprises a guide and a medical lead. The guide is similar to the first medical lead of the previously described medical kit, with the exception that it need not have an operative element.
BRIEF DESCRIPTION OF THE DRAWINGS The drawings illustrate the design and utility of embodiment(s) of the invention, in which similar elements are referred to by common reference numerals, and in which: Fig. 1 is a plan view of a modular stimulation lead kit arranged in accordance with one embodiment of the invention; Fig. 2 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 1; Fig. 3 is a cutaway perspective view of a primary stimulation lead used in the kit of Fig. 1 ; Fig. 4 is a cutaway perspective view of a secondary stimulation lead used in the kit of Fig. 1; Fig. 5 is a cross-sectional view of the stimulation lead assembly of Fig. 2, taken along the line 5-5; Fig. 6 is a cutaway view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 ; Fig. 7 is a cross-sectional view of the stimulation lead assembly of Fig. 6, taken along the line 7-7; Figs. 8A-8D are various views illustrating the installation of the kit of Fig. 1 into a patient's spine; Fig. 9 is a plan view of another modular stimulation lead kit arranged in accordance with another embodiment of the invention; Fig. 10 is a cutaway top view of a stimulation lead assembly formed from the kit of Fig. 9; Fig. 11 is a cross-sectional view of the secondary stimulation lead of Fig. 10, taken along the line 11-11 ; Figs. 12A-12B are various views illustrating the installation of the kit of Fig. 9 into a patient's spine; Fig. 13 is a partially cutaway top view of the distal end of an alternative primary stimulation lead that can be used in kit of Fig. 1 ; Fig. 14a is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads are shown in a normally curved geometry that converges towards the primary stimulation lead; Fig. 15a is a cross-sectional view of the stimulation lead assembly of Fig. 14a, taken along the line 15a-15a; Fig. 14b is a cutaway top view of an alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a stylet is introduced; Fig. 15b is a cross-sectional view of the stimulation lead assembly of Fig. 14b, taken along the line 15b-15b; Fig. 14c is a cutaway top view of another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 13 is used, wherein the secondary stimulation leads can be placed into a curved geometry that converges towards the primary stimulation lead when a pullwire is tensioned; Fig. 15c is a cross-sectional view of the stimulation lead assembly of Fig. 14c, taken along the line 15c-15c; Fig. 14d is a cutaway top view of still another alternative stimulation lead assembly that can be formed from the kit of Fig. 1 when the primary stimulation lead of Fig. 3 is used, wherein the secondary stimulation leads can be placed into a curved geometry that bows away from the primary stimulation lead; Fig. 15d is a cross-sectional view of the stimulation lead assembly of Fig. 14d, taken along the line 15d-15d; Fig. 15e is a cross-sectional view of the stimulation lead assembly of Fig. 14d, taken along the line 15e-15e; Fig. 15f is a cross-sectional view of the stimulation lead assembly of Fig. 14d, taken along the line 15f-15f; Fig. 16 is a cutaway top view of an alternative stimulation lead assembly; Fig. 17 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing an electrode flap of a secondary stimulation lead constrained by the primary stimulation lead; and Fig. 18 is a cross-sectional view of a portion of the stimulation lead assembly of Fig. 16, particularly showing the electrode flap of the secondary stimulation lead released by the primary stimulation lead.
DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS Referring now to Fig. 1 , a modular stimulation lead kit 100 arranged in accordance with one embodiment of the invention, generally comprises a primary stimulation lead 102 and two secondary stimulation leads 104, which are configured to be percutaneously delivered and implanted into the epidural space of a patient's spine, an implantable electrical stimulation source 106 configured for delivering stimulation energy to the stimulation leads 102/104, and an optional extension lead 108 configured for connecting the stimulation leads 102/104 to the remotely implanted stimulation source 106. As will be described in further detail below, the secondary stimulation leads 104 can be attached to the primary stimulation lead 102 to form a modularized stimulation lead assembly 110, as illustrated in Fig. 2. It should be noted that although the kit 100 illustrated in Fig. 1 is described herein as being used in spinal cord stimulation (SCS) for the treatment of chronic pain, the kit 100, or a modification of the kit 100, can be used in an SCS procedure to treat other ailments, or can used in other applications other than SCS procedures, such as peripheral nervous system stimulation, sacral root stimulation, and brain tissue stimulation, including cortical and deep brain stimulation. In the latter case, the stimulation leads 102/104 can be delivered through a miniature cranial burr hole into the brain tissue. The primary stimulation lead 102 comprises an elongated sheath body 112 having a proximal end 114 and a distal end 116. The sheath body 112 is composed of a suitably flexible material (such as polyurethane, silicone, etc.), which may either be resilient or non-resilient, and may be formed via an extrusion process or by any other suitable means. The distal end 116 of the sheath body 112 is soft and tapered to prevent injury to nerve roots that exit the spinal cord when delivered into the epidural space of the patient's spine. In the illustrated embodiment, the sheath body 112 is cylindrically-shaped and sized to fit through a Touhy-like needle (not shown). In this case, the diameter of the sheath body 112 is preferably less than 5 mm to allow it to be percutaneously introduced through a needle. More preferably, the diameter of the sheath body 112 is within the range of 1 mm to 3 mm, so that the primary stimulation lead 102, along with the secondary stimulation leads 104 described below, can comfortably fit within the epidural space of the patient. The sheath body 112 may have other cross-sectional geometries, such as elliptical, rectangular, triangular, etc. If rectangular, the width of the primary stimulation lead 102 can be up to 5 mm, since the width of an epidural space is greater than its height. The sheath body 112 may have an optional lumen (not shown) for receiving a stylet (not shown) that axially stiffens the sheath body 112 to facilitate percutaneous introduction of the primary stimulation lead 102 within the epidural space of the patient's spine, as will be described in further detail below. The primary stimulation lead 102 further comprises a plurality of terminals 118 (in this case, three) mounted on the proximal end 114 of the sheath body 112, and a plurality of stimulation elements, and in particular electrodes 120 (in this case, three), mounted on the distal end 116 of the sheath body 112. The terminals 118 are formed of ring-shaped elements composed of a suitable biocompatible metallic material, such as platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials, and can be mounted to the sheath body 112 in an interference fit arrangement. In the illustrated embodiment, the electrodes 120 are formed on one circumferential side of the sheath body 112 (shown best in Fig. 3) in order to focus stimulation energy in one direction, thereby maximizing energy efficiency. The electrodes 120 can be formed onto the sheath body 112 using known deposition processes, such as sputtering, vapor deposition, ion beam deposition, electroplating over a deposited seed layer, or a combination of these processes. Alternatively, the electrodes 120 can be formed onto the sheath body 112 as a thin sheet or foil of electrically conductive metal affixed to the wall of the sheath body 112. The electrodes 120 can be composed of the same electrically conductive and biocompatible material as the terminals 118, e.g., platinum, platinum/iridium, stainless steel, gold, or combinations or alloys of these materials. The primary stimulation lead 102 further comprises a plurality of conductors
122 (shown in Fig. 3) extending through the sheath body 112 and connecting each electrode 120 with a respective terminal 118. The conductors 122 are composed of a suitably electrically conductive material that exhibits the desired mechanical properties of low resistance, corrosion resistance, flexibility, and strength. Like the primary stimulation lead 102, each secondary stimulation lead 104 comprises an elongated sheath body 132 having a proximal end 134 and a distal end 136, a plurality of terminals 138 (in this case, four) mounted to the proximal end 134 of the sheath body 132, a plurality of electrodes 140 (in this case, four) mounted to the distal end 136 of the sheath body 132, and a plurality of conductors 142 (shown in Fig. 4) extending through the sheath body 132 and respectively connecting the electrodes 120 to the terminals 118. The sheath bodies 132 of the secondary stimulation leads 104 are similar to the sheath body 112 of the primary stimulation lead 102, with the exception that the distal ends 136 are tapered in only one direction. In this manner, the stimulation lead assembly 110, as illustrated in Fig. 2, forms a lower profile distal end to facilitate placement of the assembly 110 within the epidural space of the patient's spine. Like the sheath body 112 of the primary stimulation lead 102, the sheath bodies 132 of the secondary stimulation leads 104 may each have an optional lumen (not shown) for receiving a stylet (not shown) to facilitate percutaneous introduction of the secondary stimulation lead 104 within the epidural space of the patient's spine, as will be described in further detail below. The terminals 118 and electrodes 120 of the secondary stimulation leads 104 are similar to the terminals 118 and electrodes 120 of the primary stimulation lead 102, with the exception that there are four sets of terminals 118 and electrodes 120 instead of three. Notably, the electrodes 120 of the secondary stimulation leads 104 face the same direction as the electrodes 140 of the primary stimulation leads 102, so that the entire stimulation lead assembly 110 is capable of focusing electrical energy in a single direction, as shown in Fig. 3. Also, as illustrated in Fig. 3, the electrodes 120/140 are arranged on the respective sheath bodies 112/132, such that the electrodes 140 of the secondary stimulation leads 104 are offset from the electrodes 120 of the primary stimulation lead 102 in the longitudinal direction, thereby preventing accidental shorting between adjacent electrodes when the assembly 110 is formed. Further details regarding the structure and composition of standard percutaneous stimulation leads are disclosed in U.S. Patent No. 6,216,045. The primary stimulation lead 102 and the respective secondary stimulation leads 104 are configured to slidably engage each other to form the lead assembly 110 illustrated in Fig. 2. In particular, referring to Figs. 3-5, the primary stimulation lead 102 comprises a pair of circumferentially opposed slots 150 extending along the length of the sheath body 112. The slots 150 can be formed in the sheath body 112 using any one of a variety of manners, but in the illustrated embodiment, the slots 150 are formed during the extrusion process. Alternatively, the slots 150 can be formed by embedding, or otherwise mounting, discrete slotted members (not shown) along the sheath body 112. In contrast, each of the secondary stimulation leads 104 comprises a rail 152 extending along the sheath body 132. Like the slots 150, the rail 152 can be formed on the sheath body 132 using any one of a variety of manners, such as forming the rail 152 during the extrusion process. Alternatively, the rail 152 can be formed of a discrete member (not shown) that is bonded, or otherwise mounted, to the sheath body 132. In other embodiments, the primary stimulation lead 102 may have a pair of circumferentially opposed rails extending along its sheath body 112, while the secondary stimulation leads 104 may have slots 150 extending along their sheath bodies 132. In any event, the rails 152 and slots 150 are sized to snuggly engage each other in a sliding relationship, as best shown in Fig. 5. Thus, it can be appreciated that the secondary stimulation leads 104 can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming the stimulation assembly 110 illustrated in Fig. 2. The opposing slots 150 of the primary stimulation lead 102 and the rails 152 of the secondary stimulation leads 104 are circumferentially offset ninety degrees from the centers of the respective electrodes 120. In this manner, all of the electrodes 120, which generally face in the same direction, as described above, are ensured to face in a direction perpendicular to the plane of the assembly 110, thereby maximizing transmission of the stimulation energy into the target neural tissue when the assembly 110 is fully implanted within the epidural space of the patient's spine. Although a rail and slot arrangement has been disclosed as the preferred means of slidably engaging the primary and stimulation leads 102/104, other means of slidably engaging the leads can be provided. For example, instead of slots, the primary stimulation lead can have loop structures (not shown) that extend along the opposing sides the respective sheath body. The secondary stimulation leads 104 can then be introduced through the respective sets of loop structures in order to couple the leads together. In the illustrated embodiment, the slots 150 have distal rail stops (not shown), i.e., the distal ends of the slots 150 terminate prior to the distal tip of the sheath body 112 to prevent the distal ends 136 of the secondary stimulation leads 104 from sliding distal to the distal end 116 of the primary stimulation lead 102. Alternatively, the distal ends of the slots 150 may have chamfered openings 151 , as illustrated in Fig. 13. In this manner, the distal ends of the secondary stimulation leads 104 will diverge from the distal end of the primary stimulation lead 102 when the leads 102/104 are slidably engaged with each other. That is, when the rail 152 of a secondary stimulation lead 104 is slid along the respective slot 150 of the primary stimulation lead 102, the distal end of the rail 152 will be diverted out of the chamfered opening 151 at the distal end of the slot 150, thereby expanding the footprint of the resulting assembly 110, as illustrated in Fig. 14a. The secondary stimulation lead 104 may have a proximal rail stop (not shown) to prevent further sliding of the respective secondary stimulation lead 104 when fully deployed. The distal ends of the secondary stimulation leads 104 can be pre-curved inward towards the primary stimulation lead 102, as illustrated in Fig. 14a, so that the distal ends of the secondary stimulation leads 104, when deployed from the primary stimulation lead 102, extend in a parallel direction with the distal end of the primary stimulation lead 102. The distal ends of the secondary stimulation leads 104 can be pre-curved in any one of a variety of manners. For example, as illustrated in Fig. 15a, a pre-curved resilient member 153 composed of a suitable material, such as nitinol, can be formed within the sheath body 132. Preferably, the cross-section of the resilient member 153 resembles of flat plate, so that the sheath body 132 consistently bends in a pre-defined plane, i.e., within the plane of the assembly 110. Alternatively, as illustrated in Fig. 14b, the distal ends of the secondary stimulation leads 104 are not pre-curved, but rather normally exhibit a straight geometry after exiting slot 150 of the primary stimulation lead 102 (shown in phantom in Fig. 14b), such that the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102. Alternatively, the distal ends of the secondary stimulation leads 104 may not be resilient. In either case, the secondary stimulation lead 104 comprises a lumen 155 through which a curved stylet 157 is introduced, as illustrated in Fig. 15b. The distal end of the stylet 157 is curved, such that, when introduced through the lumen 155, the distal end of the respective stimulation lead 104 assumes a geometry that curves inward towards the primary stimulation lead 102, as illustrated in Fig. 14b. Differently curved stylets 157 can be used in order to provide the distal end of the secondary stimulation lead 104 with the desired curved geometry. Alternatively, rather than providing a curved stylet 157 and a normally straight secondary stimulation lead 104, the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig. 14a. In this case, the distal end of the stylet 157 can be straight, so that its introduction through the lumen 157 straightens the pre-curved distal end of the secondary stimulation lead 104, as shown in phantom in Fig. 14b. As another alternative, a steering mechanism can be used to control the shape of the secondary stimulation lead 104. In particular, as illustrated in Fig. 14c, the distal ends of the secondary stimulation leads 104 normally exhibit a straight geometry, in which case, the resilient member 153 is likewise formed into a straight geometry. As illustrated in Fig. 15c, the secondary stimulation lead 104 comprises a pullwire lumen 159 and an associated pullwire 161 mounted to the inside surface of the distal end of the resilient member 153. When the pullwire 161 is relaxed, the distal end of the secondary stimulation lead 104 assumes the straight geometry. In this case, the distal ends of the secondary stimulation leads 104 diverge from the primary stimulation lead 102, as illustrated in Fig. 14c. In contrast, when the pullwire 161 is pulled, the distal end of the secondary stimulation lead 104 assumes a geometry (shown in phantom) that curves inward towards the primary stimulation lead 102. Notably, the proximal-most portion of the distal ends of the secondary stimulation leads 104 does not contain the resilient member 153, so that the respective stimulation lead 104 bends at this portion when the pullwire 161 is pulled. Rather than providing a normally straight secondary stimulation lead 104, the distal end of the secondary stimulation lead 104 can be pre-curved much like the stimulation lead 104 illustrated in Fig. 14a. In this case, the pullwire 161 can be mounted to the outside surface of the distal end of the resilient member 153, such that relaxation of the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a curved geometry that converges towards the primary stimulation lead 102, whereas the application of tension on the pullwire 161 causes the distal end of the secondary stimulation lead 104 to assume a lesser curved or straight geometry that diverges from the primary stimulation lead 102. As still another alternative, a portion of the secondary stimulation lead 104 may not have a rail, so that it bows outward after the primary stimulation lead 102 and secondary stimulation lead 104 are fully engaged, as illustrated in Fig. 14d. As best seen in Figs. 15d-f , the rail 152 extends along the distal-most and proximal- most portions of the distal end of the second stimulation lead 104, but does not extend along a medial-portion of the distal end of the second stimulation lead 104. As a result, after the distal end of the respective rail 152 (i.e., the rail 152 located on the distal-most portion of the second stimulation lead 104) abuts the distal rail stop (not shown) in the corresponding slot 150, further distal movement of the secondary stimulation lead 104 relative to the primary stimulation lead 102 causes the medial- portion, which is not engaged with the slot 150 of the primary stimulation lead 102, to bow outward from a straight geometry (shown in phantom). In contrast, proximal movement of the secondary stimulation lead 104 relative to the primary stimulation lead 102 causes the medial-portion to return from the bowed geometry back to its straight geometry. It should be noted that although the assemblies 110 illustrated in Figs. 2 and
14a-d are formed of three stimulation leads, less or more than three stimulation leads can be used. For example, if an assembly formed only of two stimulation leads is desired, only one slot 150 on the primary stimulation lead 102 is required. In this case, the primary stimulation lead 102 may only have one slot 150 formed along one side of the respective body 112, or alternatively, if the primary stimulation lead 102 comprises two opposing slots 150, only one will be used to couple the lone secondary stimulation lead 104 thereto. On the other hand, if an assembly formed of more than three stimulation leads is desired, the secondary stimulation leads 104 may have a pair of circumferentially opposed rails 152. For example, if there are five stimulation leads, two secondary stimulation leads 103 (which are similar to the secondary stimulation leads 104, but with a pair of circumferentially opposing rails 152) can be coupled to the primary stimulation lead 102 by sliding the rails 152 of the respective secondary stimulation leads 104 along the respective slots 150 of the primary stimulation lead 102, thereby forming a partial assembly similar to that illustrated in Fig. 3. Then, two additional secondary stimulation leads 105 (which are similar to secondary stimulation leads 105, but have a pair of circumferentially opposed slots 150) can be coupled to the secondary stimulation leads 105 by sliding the slots 150 of the additional secondary stimulation leads 102 along the respective rails 152, thereby forming a full assembly 160, as illustrated in Figs. 6 and 7. Referring back to Fig. 1 , the implantable stimulation source 106 is designed to deliver electrical pulses to the stimulation leads 102/104 in accordance with programmed parameters. In one embodiment, the stimulation source 106 is programmed to output electrical pulses having amplitudes varying from 0.1 to 20 volts, pulse widths varying from 0.02 to 1.5 milliseconds, and repetition rates varying from 2 to 2500 Hertz. In the illustrated embodiment, the stimulation source 106 takes the form of a totally self-contained generator, which once implanted, may be activated and controlled by an outside telemetry source, e.g., a small magnet. In this case, the pulse generator has an internal power source that limits the life of the pulse generator to a few years, and after the power source is expended, the pulse generator must be replaced. Generally, these types of stimulation sources 106 may be implanted within the chest or abdominal region beneath the skin of the patient. Alternatively, the implantable stimulation source 106 may take the form of a passive receiver that receives radio frequency (RF) signals from an external transmitter worn by the patient. In this scenario, the life of the stimulation source 106 is virtually unlimited, since the stimulation signals originate from the external transmitter. Like the self-contained generators, the receivers of these types of stimulation sources 106 can be implanted within the chest or abdominal region beneath the skin of the patient. The receivers may also be suitable for implantation behind the ear of the patient, in which case, the external transmitter may be worn on the ear of the patient in a manner similar to that of a hearing aid. Stimulation sources, such as those just described, are commercially available from Advanced Neuromodulation Systems, Inc., located in Piano, Texas, and Medtronic, Inc., located in Minneapolis, Minnesota. The optional extension lead 108 comprises an elongated sheath body 144 having a proximal end 146 and a distal end 148, much like the sheath bodies
112/132 of the stimulation leads 102/104, a distal adapter 154 coupled to the distal end 148 of the sheath body 144, a connector 156 coupled to the proximal end 146 of the sheath body 144, and a plurality of electrical conductors (not shown) extending through the sheath body 144. The length of the extension lead 108 is sufficient to extend from the spine of the patient, where the proximal ends of the implanted stimulation leads 102/104 protrude from to the implantation site of the stimulation source 106 — typically somewhere in the chest or abdominal region. The distal adapter 154 is configured to receive the proximal ends of the stimulation leads 102/104, and the proximal connector 156 is configured to couple to the stimulation source 106. Having described the stimulation lead kit 100, its installation and use in treating chronic pain will now be described with reference to Figs. 8A-8D. After the patient has been prepared (which may involve testing the efficacy of spinal cord stimulation on the patient, and, once determining that the patient can be effectively treated with spinal cord stimulation, identifying and marking the appropriate vertebral intervals on the patient's skin and applying a local anesthetic to this region), a needle 10, such as, e.g., a Touhy needle, is inserted through the patient's skin 12 between the desired vertebrae 14, and into the epidural space 16 within the spine at a position inferior to target stimulation site 18 (Fig. 8A). In the illustrated method, the Touhy needle 10 will serve as the primary delivery mechanism for the primary stimulation lead 102. Alternatively, if an optional introducer (not shown) is used, a guide wire (not shown) is introduced through the needle 10 and advanced to or near the target stimulation site 18. The needle 10 is removed, the introducer is then introduced over the guide wire and advanced to the target stimulation site 18, and the guide wire is then withdrawn. In this case, the introducer will serve as the primary delivery mechanism for the primary stimulation lead 102. After the deliver mechanism is in place, the primary stimulation lead 102 is then inserted through the needle or the introducer (whichever is in place), and positioned in the epidural space at the target stimulation site 18, with the electrodes 120 facing the dural layer 20 surrounding the spinal cord 22 (Fig. 8B). If the primary stimulation lead 102 has a stylet lumen, a stylet can be used to provide additional axial stiffness and to facilitate control. Next, the needle 10 or introducer is removed, and one of the secondary stimulation leads 104 is delivered through the percutaneous opening 24 left by the removal of the needle 10, and into the epidural space 16 by slidably engaging the secondary stimulation lead 104 along the primary stimulation lead 102 (Fig. 8C). In particular, the rail 152 of the secondary stimulation lead 104 is inserted into the corresponding slot 150 of the primary stimulation lead 102, and the secondary stimulation lead 104 is pushed until the distal end of the rail 152 abuts the distal end of the slot 150, thereby signifying that the secondary stimulation lead 104 is fully engaged with the primary stimulation lead 102 (with the electrodes 120/140 of the stimulation leads 102/104 adjacent, but offset from, each other) and is in its proper location within the epidural space 16 of the patient. The other secondary stimulation lead 104 is then delivered into the epidural space by slidably engaging it along the primary stimulation lead 102 in the same manner, thereby completing the stimulation lead assembly 110 (Fig. 8D). If the secondary stimulation leads 104 have stylet lumens, a stylet can be used to provide additional axial stiffness and to facilitate control. Once the assembly 110 is completed, the electrodes 120/140 will span the midline of the spinal cord 22, much like the electrodes of a standard surgical lead do. Next, the proximal ends of the stimulation leads 102/104 are connected to a tester (not shown), which is then operated in a standard manner to confirm proper location of the stimulation lead assembly 110 and to adjust the stimulation parameters for optimal pain relief. Once this optimization process has been completed, the tester is disconnected from the stimulation leads 102/104, which are then anchored in place using standard lead anchors (not shown). Next, the stimulation lead assembly 110 is coupled to the stimulation source 106 and implantation is completed (not shown). In particular, a subcutaneous pocket is created in the patient's abdominal area for implantation of the stimulation source 106, and a tunnel is subcutaneously formed between the spine region and the subcutaneous pocket. The optional lead extension 108 is passed through the tunnel, after which the adapter 154 of the extension 108 is connected to the proximal ends of the stimulation leads 102/104 and the connector 156 of the lead extension 108 is connected to the stimulation source 106. The stimulation source 106 is programmed and tested, and then placed within the subcutaneous pocket, after which all incisions are closed to effect implantation of the stimulation lead assembly 110 and stimulation source 106. The stimulation source 106 can then be operated to convey stimulation energy from the stimulation source 106 to the electrodes 120/140 of the stimulation lead assembly 110, where it is, in turn, conveyed into the neural tissue for pain relief. If necessary or desired, e.g., if the electrodes 120/140 malfunction or stimulation otherwise ceases to provide therapeutic benefit, the stimulation lead assembly 110 can be subsequently retrieved from the patient's spine by removing the assembly 110 at the same time or by removing the assembly one stimulation lead 102/104 at a time by slidably disengaging the stimulation leads 102/104. In the case of the assembly 110 illustrated in Fig. 14, the rail and slot arrangement will pull the deployed distal end of the secondary stimulation leads 104 along side of the primary stimulation lead 102 when retrieved. It can be appreciated that the relatively large footprint made by the stimulation lead assembly 110, much like a prior art surgical lead, provides a more stable platform for the electrodes 120/140. Also, like a prior art surgical lead, the electrodes 120/140 face in a single direction, thereby focusing the stimulation energy into the affected neural tissue where it is needed. Unlike a surgical lead, however, the stimulation lead assembly 110 can be percutaneously delivered into the patient's spine in a minimally invasive and relatively pain-free manner, without requiring extensive patient recovery. Referring now to Fig. 9, a modular stimulation lead kit 200 arranged in accordance with another embodiment of the invention is shown. The kit 200 is similar to the previously described kit 100, with the exception that the kit 200 comprises secondary stimulation leads 204 that minimize the profile of the resulting assembly (shown in Fig. 10), as it exits the spine of the patient. In particular, each secondary stimulation lead 204 comprises a shortened sheath body 232, electrodes 240 mounted to the sheath body 232, electrical conductors 242 extending from the sheath body 232, and a connector 244 that receives the proximal ends of the electrical conductors 242. The connector 244 comprises a plurality of terminals 238 that are similar to the previously described lead terminals 138. The sheath body 232 is composed of the same material and has the same general shape as the sheath body 132 of the previously described secondary stimulation lead 104. The sheath body 232, as illustrated in Fig. 9, however, is much shorter, so that it can be entirely received within the epidural space of the patient, i.e., the sheath body 232 will not extend out of the patient's back when fully deployed within the epidural space. The electrical conductors 242, because they are exposed, are preferably composed of an electrically insulative material. The kit 200 further comprises a pusher 214 that can be used to facilitate introduction of the respective secondary stimulation lead 204 along the primary stimulation lead 102 once the entire sheath body 232 of the secondary stimulation lead 204 is within the patient's back. The pusher 214 comprises a cylindrical rod 216 having a distal tip 218 and a proximal end 220, and a handle 222 mounted on the proximal end 220 of the rod 216. The distal tip 218 of the rod 216 is adapted to be received within an opening 224 (shown in Fig. 11) at the proximal end of the sheath body 232, thereby facilitating stable engagement between the pusher 214 and respective secondary stimulation lead 204. The kit 200 can be installed and used in the same manner as the previously described kit 100 in treating chronic pain. In particular, the patient is prepared and the primary stimulation lead 102 is delivered into the epidural space 16 of the patient's spine, so that the electrodes 120 are placed adjacent the target stimulation "site 18 in the same manner described above with respect to Fig. 8A and 8B. One of the secondary stimulation leads 204 is then delivered into the epidural space 16 in the same manner as the secondary stimulation lead 104 described above was delivered, with the exception that the pusher 214 is used to advance the secondary stimulation lead 204 along the primary stimulation lead 102 until fully deployed within the epidural space 16 (Fig. 12A). The remaining stimulation lead 204 is delivered into the epidural space 16 in the same manner to complete the stimulation lead assembly 210 (Fig. 12B). Notably, because the percutaneous opening 24 need only support, at most, two sheath bodies at one time, it can be made smaller, or alternatively, additional stimulation leads with shortened sheath bodies can be introduced within the epidural space 16 without increasing the size of the percutaneous opening. After the stimulation lead assembly 210 has been formed within the epidural space, it is tested and optimized. The extension lead 108 is then connected between the stimulation leads 102/204 and the stimulation source 106, and the incisions are closed to fully implant the system, as previously described above. Referring now to Fig. 16, an alternative embodiment of a secondary stimulation lead 304 engaged with one side of the primary stimulation 102 is illustrated. Although not shown, another secondary stimulation lead 304 can be engaged with the opposite side of the primary stimulation lead 102. The secondary stimulation lead 304 is similar to the previously described secondary stimulation lead 104, with the exception that the secondary stimulation lead 304 comprises a flap 303 on which the electrodes 140 are mounted. The secondary stimulation lead 304 can, alternatively, have a shortened sheath body much like the secondary stimulation lead 204 illustrated in Fig. 9. The flap 303 is designed to be constrained by the primary stimulation lead 102 to facilitate percutaneous delivery of the secondary stimulation lead 102, and released by the primary stimulation lead 102 to deploy the electrodes 140 into contact with the neural tissue. In particular, the edge of the flap 303 comprises a coupling mechanism 305 that is designed to fit snugly within the respective slot 150 of the primary stimulation lead 102, along with the rail 152 of the secondary stimulation lead 102, when the secondary stimulation lead 304 is slidably engaged with the primary stimulation lead 102, as illustrated in Fig. 17. As the rail 152 of the secondary stimulation lead 102 exits the slot 150 of the primary stimulation lead 102, however, the coupling mechanism 305 of the flap 303 will release from the slot 150, thereby allowing the flap 303 to deploy, placing the electrodes 140 into contact with the underlying tissue, as illustrated in Fig. 18. It should be noted, that, when the secondary stimulation lead 304 is used in the kit 100 or kit 200, the slots 150 in the primary stimulation lead 102 will not terminate as hereinbefore described, but will rather open up at the distal tip of the primary stimulation lead 102, so that the flap 303 can exit the respective slot 150 and be released by the primary stimulation lead 102. Installation and use of the secondary stimulation lead 304 in forming the stimulation lead assembly 110 illustrated in Fig. 2, or alternatively the stimulation lead assembly 210 illustrated in Fig. 10, is similar that previously described above. Although in all of the previous embodiments, the primary stimulation lead 102 was used to provide a means of guiding the secondary stimulation leads 104 into the percutaneous opening within the patient and adjacent the target tissue region, as well as to provide a means of stimulating the tissue region, a guide member similar to the primary stimulation lead 102, but lacking stimulation capability, can be alternatively used to similarly guide the secondary stimulation leads 104 through the percutaneous opening to the target tissue region. In this case, only the secondary stimulation leads 104 will be used to stimulate tissue.

Claims

1. A stimulation kit, comprising: a first tissue stimulation lead comprising a first elongated body, a first stimulation element, and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body; and a second tissue stimulation lead comprising a second elongated body, a second stimulation element, and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism.
2. The stimulation kit of claim 1 , wherein at least one of the first and second elongated bodies is cylindrically-shaped.
3. The stimulation kit of claims 1 or 2, wherein the greatest cross- sectional dimension of at least one of the first and second elongated bodies is 5 mm or less.
4. The stimulation kit of any of claims 1 - 3, wherein the first and second stimulation elements are electrodes.
5. The stimulation kit of any of claims 1 - 4, wherein the first and second stimulation elements are mounted on the respective first and second elongated bodies.
6. The stimulation kit of any of claims 1 - 5, wherein the first and second stimulation elements are configured to face a single direction when the first complementary coupling mechanism slidably engages the first coupling mechanism.
7. The stimulation kit of any of claims 1 - 6, wherein each of the first and second stimulation leads comprises a plurality of stimulation elements.
8. The stimulation kit of any of claims 1 - 7, wherein the first coupling mechanism and first complementary coupling mechanism are configured to slidably engage each other in a rail and slot arrangement.
9. The stimulation kit of any of claims 1 - 8, wherein the second complementary coupling mechanism extends along only a distal portion of the second elongated body.
10. The stimulation kit of any of claims 1 - 9, wherein the second elongated body is shorter than the first elongated body.
11. The stimulation kit of claim 1 , wherein the second elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementary coupling mechanism from the coupling mechanism.
12. The stimulation kit of claim 11 , wherein the second elongated body is pre-curved.
13. The stimulation kit of claim 11 , wherein the second elongated body is configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body.
14. The stimulation kit of claim 13, further comprising a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry.
15. The stimulation kit of claim 13, wherein the second stimulation lead comprises a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry.
16. The stimulation kit of claim 1 , wherein the second elongated body, and the second elongated body is configured to deploy from the first elongated body by bowing the portion of the second elongated body away from the first elongated body.
17. The stimulation kit of claim 1 , wherein the second stimulation lead comprises a flap on which the respective stimulation element is disposed, the flap extending along a portion of the complementary coupling mechanism, and configured to be secured by the coupling mechanism when the portion of the complementary coupling mechanism slidably engages the coupling mechanism and released by the coupling mechanism when the portion of the complementary coupling mechanism slidably disengages the coupling mechanism.
18. The stimulation kit of claim 1 , wherein the first stimulation lead comprises another coupling mechanism longitudinally extending along at least a portion of the first elongated body, the stimulation kit further comprising a third stimulation lead comprising a third elongated body, a stimulation element mounted on the third elongated body, and another complementary coupling mechanism configured to slidably engage the other coupling mechanism.
19. The stimulation kit of any of claims 1 - 18, further comprising a stimulation source configured to be coupled to the first and second stimulation leads.
20. A stimulation kit, comprising: a primary tissue stimulation lead comprising a primary elongated body, a primary stimulation element mounted on the elongated body, first and second coupling mechanisms longitudinally extending along at least a portion of the elongated body, the first and second coupling mechanisms being substantially opposite each other; and two secondary tissue stimulation leads, each comprising a secondary elongated body, a secondary stimulation element mounted to the secondary elongated body, and a complementary coupling mechanism, wherein the complementary coupling mechanisms are configured to slidably engage the respective first and second coupling mechanisms.
21. A stimulation kit, comprising: a guide comprising a first elongated body and a first coupling mechanism longitudinally extending along at least a portion of the first elongated body; and a tissue stimulation lead comprising a second elongated body, a stimulation element, and a first complementary coupling mechanism configured to slidably engage the first coupling mechanism.
22. The stimulation kit of claim 21 , wherein the first elongated body is cylindrically-shaped.
23. The stimulation kit of either of claims 21 - 22, wherein the greatest cross-sectional dimension of the first elongated body is 5 mm or less.
24. The stimulation kit of any of claims 21 - 23, wherein the stimulation element is mounted on the elongated body.
25. The stimulation kit of any of claims 21 - 24, wherein the stimulation lead comprises a plurality of stimulation elements.
26. The stimulation kit of any of claims 21 - 25, wherein the first coupling mechanism and first complementary coupling mechanism are configured to slidably engage each other in a rail and slot arrangement.
27. The stimulation kit of claim 21 , wherein the second elongated body is configured to deploy from the first elongated body by slidably disengaging at least a portion of the complementary coupling mechanism from the coupling mechanism.
28. The stimulation kit of claim 27, wherein the second elongated body is pre-curved.
29. The stimulation kit of claim 27, wherein the second elongated body is configured to be actively changed from a first geometry to a second geometry after deployment from the first elongated body.
30. The stimulation kit of claim 29, further comprising a stylet configured to be introduced through the second elongated body to change the second elongated body from the first geometry to the second geometry.
31. The stimulation kit of claim 29, wherein the stimulation lead comprises a pullwire configured to be pulled to change the second elongated body from the first geometry to the second geometry.
PCT/US2005/007179 2004-03-12 2005-03-02 Modular stimulation lead network WO2005089861A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT05724681T ATE510580T1 (en) 2004-03-12 2005-03-02 MODULAR STIMULATION LINE NETWORK
JP2007502876A JP4635045B2 (en) 2004-03-12 2005-03-02 Modular stimulation lead network
EP05724681A EP1722846B1 (en) 2004-03-12 2005-03-02 Modular stimulation lead network
CA002557743A CA2557743A1 (en) 2004-03-12 2005-03-02 Modular stimulation lead network

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/799,271 US7590454B2 (en) 2004-03-12 2004-03-12 Modular stimulation lead network
US10/799,271 2004-03-12

Publications (1)

Publication Number Publication Date
WO2005089861A1 true WO2005089861A1 (en) 2005-09-29

Family

ID=34920478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/007179 WO2005089861A1 (en) 2004-03-12 2005-03-02 Modular stimulation lead network

Country Status (7)

Country Link
US (2) US7590454B2 (en)
EP (1) EP1722846B1 (en)
JP (1) JP4635045B2 (en)
AT (1) ATE510580T1 (en)
CA (1) CA2557743A1 (en)
ES (1) ES2363086T3 (en)
WO (1) WO2005089861A1 (en)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7072719B2 (en) * 2001-09-20 2006-07-04 Medtronic, Inc. Implantable percutaneous stimulation lead with interlocking elements
US20050203600A1 (en) * 2004-03-12 2005-09-15 Scimed Life Systems, Inc. Collapsible/expandable tubular electrode leads
US7590454B2 (en) 2004-03-12 2009-09-15 Boston Scientific Neuromodulation Corporation Modular stimulation lead network
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US8082039B2 (en) 2004-09-08 2011-12-20 Spinal Modulation, Inc. Stimulation systems
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
US7918849B2 (en) 2004-10-15 2011-04-05 Baxano, Inc. Devices and methods for tissue access
US7555343B2 (en) 2004-10-15 2009-06-30 Baxano, Inc. Devices and methods for selective surgical removal of tissue
US9247952B2 (en) 2004-10-15 2016-02-02 Amendia, Inc. Devices and methods for tissue access
US8221397B2 (en) 2004-10-15 2012-07-17 Baxano, Inc. Devices and methods for tissue modification
US8257356B2 (en) 2004-10-15 2012-09-04 Baxano, Inc. Guidewire exchange systems to treat spinal stenosis
US20110190772A1 (en) 2004-10-15 2011-08-04 Vahid Saadat Powered tissue modification devices and methods
US7938830B2 (en) 2004-10-15 2011-05-10 Baxano, Inc. Powered tissue modification devices and methods
US7578819B2 (en) 2005-05-16 2009-08-25 Baxano, Inc. Spinal access and neural localization
US8617163B2 (en) 2004-10-15 2013-12-31 Baxano Surgical, Inc. Methods, systems and devices for carpal tunnel release
US7857813B2 (en) 2006-08-29 2010-12-28 Baxano, Inc. Tissue access guidewire system and method
US8048080B2 (en) 2004-10-15 2011-11-01 Baxano, Inc. Flexible tissue rasp
US20100331883A1 (en) 2004-10-15 2010-12-30 Schmitz Gregory P Access and tissue modification systems and methods
US7887538B2 (en) 2005-10-15 2011-02-15 Baxano, Inc. Methods and apparatus for tissue modification
US9101386B2 (en) 2004-10-15 2015-08-11 Amendia, Inc. Devices and methods for treating tissue
US8062300B2 (en) 2006-05-04 2011-11-22 Baxano, Inc. Tissue removal with at least partially flexible devices
US8430881B2 (en) 2004-10-15 2013-04-30 Baxano, Inc. Mechanical tissue modification devices and methods
US7738969B2 (en) 2004-10-15 2010-06-15 Baxano, Inc. Devices and methods for selective surgical removal of tissue
US20080103504A1 (en) * 2006-10-30 2008-05-01 Schmitz Gregory P Percutaneous spinal stenosis treatment
US9050455B2 (en) 2004-10-21 2015-06-09 Medtronic, Inc. Transverse tripole neurostimulation methods, kits and systems
US7657316B2 (en) * 2005-02-25 2010-02-02 Boston Scientific Neuromodulation Corporation Methods and systems for stimulating a motor cortex of the brain to treat a medical condition
US7267690B2 (en) 2005-03-09 2007-09-11 Vertebral Technologies, Inc. Interlocked modular disc nucleus prosthesis
US8366712B2 (en) 2005-10-15 2013-02-05 Baxano, Inc. Multiple pathways for spinal nerve root decompression from a single access point
US8062298B2 (en) 2005-10-15 2011-11-22 Baxano, Inc. Flexible tissue removal devices and methods
US8092456B2 (en) 2005-10-15 2012-01-10 Baxano, Inc. Multiple pathways for spinal nerve root decompression from a single access point
US8612009B2 (en) 2006-01-26 2013-12-17 Advanced Neuromodulation Systems, Inc. Method of neurostimulation of distinct neural structures using single paddle lead to treat multiple pain locations and multi-column, multi-row paddle lead for such neurostimulation
WO2007087626A2 (en) * 2006-01-26 2007-08-02 Advanced Neuromodulation Systems, Inc. Method of neurosimulation of distinct neural structures using single paddle lead
US7467016B2 (en) * 2006-01-27 2008-12-16 Cyberonics, Inc. Multipolar stimulation electrode with mating structures for gripping targeted tissue
EP1981584B1 (en) 2006-02-03 2015-05-13 Interventional Autonomics Corporation Intravascular device for neuromodulation
US20080046058A1 (en) * 2006-04-28 2008-02-21 Cross Thomas E Methods for customizing implantable medical lead assemblies with improved flexibility and extensibility
US20070282410A1 (en) * 2006-04-28 2007-12-06 Cross Thomas E Jr Implantable medical lead assemblies with improved flexibility and extensibility and having a substantially two-dimensional nature
US9737414B2 (en) 2006-11-21 2017-08-22 Vertebral Technologies, Inc. Methods and apparatus for minimally invasive modular interbody fusion devices
US9314618B2 (en) 2006-12-06 2016-04-19 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
AU2007329252A1 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Hard tissue anchors and delivery devices
US9427570B2 (en) * 2006-12-06 2016-08-30 St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) Expandable stimulation leads and methods of use
JP5414531B2 (en) 2006-12-06 2014-02-12 スパイナル・モデュレーション・インコーポレイテッド Delivery device and systems and methods for stimulating neural tissue at multiple spinal levels
US7797054B2 (en) * 2007-01-12 2010-09-14 Medtronic, Inc. Expandable systems for medical electrical stimulation
EP2111253B1 (en) * 2007-01-29 2018-05-02 Spinal Modulation, Inc. Sutureless lead retention features
FR2912921B1 (en) * 2007-02-26 2010-10-08 Commissariat Energie Atomique NON-RECTILINE PROBE AND SYSTEM FOR DEEP ELECTRICAL NEUROSTIMULATION COMPRISING SUCH A PROBE
US8224453B2 (en) * 2007-03-15 2012-07-17 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat pain
WO2008130408A1 (en) * 2007-04-20 2008-10-30 Medtronic, Inc. Implantable medical electrical lead and connector assembly
US20080269858A1 (en) * 2007-04-30 2008-10-30 Cross Thomas E Implantable medical leads with flexibility and extensibility, and having a substantially two-dimensional nature
US7996090B2 (en) * 2007-04-30 2011-08-09 Medtronic, Inc. Methods of making implantable medical leads with a non-linear shape
US7725198B2 (en) * 2007-04-30 2010-05-25 Medtronic, Inc. Implantable medical lead assemblies with delivery tether
US20080269857A1 (en) * 2007-04-30 2008-10-30 Cross Thomas E Implantable medical leads and lead assemblies with flexibility, extensibility and branched structures
WO2009032363A1 (en) 2007-09-06 2009-03-12 Baxano, Inc. Method, system and apparatus for neural localization
US9089707B2 (en) 2008-07-02 2015-07-28 The Board Of Regents, The University Of Texas System Systems, methods and devices for paired plasticity
US8457757B2 (en) 2007-11-26 2013-06-04 Micro Transponder, Inc. Implantable transponder systems and methods
US7751904B2 (en) * 2007-11-29 2010-07-06 Biotronik Crm Patent Ag Electrode lead for implantation into a small heart vessel
US8192436B2 (en) 2007-12-07 2012-06-05 Baxano, Inc. Tissue modification devices
EP2252364B1 (en) * 2008-02-15 2012-06-20 Cardiac Pacemakers, Inc. Medical electrical lead with proximal armoring
WO2009102972A1 (en) * 2008-02-15 2009-08-20 Cardiac Pacemakers, Inc. Modular, zone-specific medical electrical lead design
US7925352B2 (en) 2008-03-27 2011-04-12 Synecor Llc System and method for transvascularly stimulating contents of the carotid sheath
US8326439B2 (en) 2008-04-16 2012-12-04 Nevro Corporation Treatment devices with delivery-activated inflatable members, and associated systems and methods for treating the spinal cord and other tissues
WO2009143177A2 (en) * 2008-05-19 2009-11-26 Nevro Corporation Implantable neural stimulation electrode assemblies and methods for stimulating spinal neural sites
US9314253B2 (en) 2008-07-01 2016-04-19 Amendia, Inc. Tissue modification devices and methods
US8398641B2 (en) 2008-07-01 2013-03-19 Baxano, Inc. Tissue modification devices and methods
US8409206B2 (en) 2008-07-01 2013-04-02 Baxano, Inc. Tissue modification devices and methods
CA2730732A1 (en) 2008-07-14 2010-01-21 Baxano, Inc. Tissue modification devices
EP2303196B1 (en) 2008-07-23 2018-10-24 Marc I. Malberg Modular nucleus pulposus prosthesis
US9364338B2 (en) 2008-07-23 2016-06-14 Resspond Spinal Systems Modular nucleus pulposus prosthesis
US9717910B2 (en) * 2008-09-04 2017-08-01 Boston Scientific Neuromodulation Corporation Multiple tunable central cathodes on a paddle for increased medial-lateral and rostral-caudal flexibility via current steering
US8556940B2 (en) 2008-10-01 2013-10-15 Sherwin Hua System and method for wire-guided pedicle screw stabilization of spinal vertebrae
EP2373378B1 (en) 2008-10-27 2017-04-26 Spinal Modulation Inc. Selective stimulation systems and signal parameters for medical conditions
US20100137960A1 (en) * 2008-12-03 2010-06-03 Boston Scientific Neuromodulation Corporation Implantable neurostimulators having reduced pocket stimulation
JP5582619B2 (en) 2009-03-13 2014-09-03 バクサノ,インク. Flexible nerve position determination device
CA2758459A1 (en) 2009-03-24 2010-10-30 Spinal Modulation, Inc. Pain management with stimulation subthreshold to paresthesia
AU2010248802B2 (en) * 2009-05-15 2017-02-02 Spinal Modulation, Inc. Methods, systems and devices for neuromodulating spinal anatomy
US8394102B2 (en) 2009-06-25 2013-03-12 Baxano, Inc. Surgical tools for treatment of spinal stenosis
US20110009933A1 (en) * 2009-07-09 2011-01-13 Boston Scientific Neuromodulation Corporation Piggy-back percutaneous lead insertion kit
WO2011014592A2 (en) * 2009-07-30 2011-02-03 Richard North Modular electrode and insertion tool
JP2011036284A (en) * 2009-08-06 2011-02-24 Terumo Corp Electric stimulator
EP2462981A4 (en) * 2009-08-06 2013-01-23 Terumo Corp Electric stimulator
US8670837B2 (en) * 2010-03-24 2014-03-11 Khosrow Daneshvar Method and means to adjust the positioning of stimulating neural and muscular electrode
US11045221B2 (en) * 2009-10-30 2021-06-29 Medtronic, Inc. Steerable percutaneous paddle stimulation lead
WO2011103530A2 (en) 2010-02-22 2011-08-25 North Richard B Percutaneous electrode
CN103079489B (en) 2010-05-10 2016-11-16 脊髓调制公司 For reducing the mthods, systems and devices of migration
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
US8965482B2 (en) 2010-09-30 2015-02-24 Nevro Corporation Systems and methods for positioning implanted devices in a patient
CA2823592C (en) 2011-01-03 2021-11-23 The Regents Of The University Of California High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
KR20140038940A (en) 2011-01-21 2014-03-31 캘리포니아 인스티튜트 오브 테크놀로지 A parylene-based microelectrode array implant for spinal cord stimulation
AU2012212150B2 (en) 2011-02-02 2016-09-29 Spinal Modulation, Inc Devices, systems and methods for the targeted treatment of movement disorders
JP6060146B2 (en) 2011-03-24 2017-01-11 カリフォルニア インスティテュート オブ テクノロジー Nerve stimulator
AU2012318586B2 (en) 2011-10-04 2017-06-08 Nevro Corporation Modeling positions of implanted devices in a patient
US9682227B2 (en) * 2011-10-07 2017-06-20 Anthony J. Colantonio Lead coupler for multiple neurological stimulation leads
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
ES2728143T3 (en) 2011-11-11 2019-10-22 Univ California Transcutaneous spinal cord stimulation: non-invasive tool for locomotor circuit activation
CN104220128B (en) 2011-11-11 2016-12-07 神经赋能科技公司 Enable the non-intruding neuroregulation device that motor function, sensory function, autonomic nervous function, sexual function, vasomotoricity and cognitive function recover
EP2790773B1 (en) 2012-01-25 2020-10-14 Nevro Corporation Lead anchor
WO2013112905A1 (en) * 2012-01-26 2013-08-01 Boston Scientific Neuromodulation Corporation Systems and methods for identifying the circumferential positioning of electrodes of leads for electrical stimulation systems
US9510953B2 (en) 2012-03-16 2016-12-06 Vertebral Technologies, Inc. Modular segmented disc nucleus implant
US9308022B2 (en) 2012-12-10 2016-04-12 Nevro Corporation Lead insertion devices and associated systems and methods
US9457195B2 (en) 2013-01-10 2016-10-04 Konstantin V. Slavin Implantable medical device
US9993642B2 (en) 2013-03-15 2018-06-12 The Regents Of The University Of California Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
US9731122B2 (en) 2013-04-29 2017-08-15 Rainbow Medical Ltd. Electroosmotic tissue treatment
US9919146B2 (en) 2013-05-01 2018-03-20 Sherwin Hua Methods and systems for intraventricular brain stimulation
US9265935B2 (en) 2013-06-28 2016-02-23 Nevro Corporation Neurological stimulation lead anchors and associated systems and methods
AU2014324660A1 (en) 2013-09-27 2016-04-21 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
WO2015106286A1 (en) 2014-01-13 2015-07-16 California Institute Of Technology Neuromodulation systems and methods of using same
US10265530B1 (en) 2014-05-29 2019-04-23 Stimwave Technologies Incorporated Simulation with electrode arrays
AU2015305237B2 (en) 2014-08-21 2020-06-18 The Regents Of The University Of California Regulation of autonomic control of bladder voiding after a complete spinal cord injury
CA2959378A1 (en) 2014-08-27 2016-03-03 The Regents Of The University Of California Multi-electrode array for spinal cord epidural stimulation
US10271899B2 (en) * 2015-03-18 2019-04-30 Medtronic Cryocath Lp Multi-function device with treatment and sensing capabilities
US9616221B2 (en) 2015-07-08 2017-04-11 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease
US11298533B2 (en) 2015-08-26 2022-04-12 The Regents Of The University Of California Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject
US10155107B2 (en) * 2015-10-07 2018-12-18 Medtronic, Inc. Implantable modular electrode array assembly
US10898716B2 (en) 2015-10-29 2021-01-26 Rainbow Medical Ltd. Electrical substance clearance from the brain
US11097122B2 (en) 2015-11-04 2021-08-24 The Regents Of The University Of California Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel
US9770591B2 (en) 2015-12-29 2017-09-26 Rainbow Medical Ltd. Disc therapy
US11484706B2 (en) 2015-12-29 2022-11-01 Discure Technologies Ltd Disc therapy
US10569086B2 (en) 2017-01-11 2020-02-25 Rainbow Medical Ltd. Electrical microglial cell activation
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US10758722B2 (en) 2017-05-03 2020-09-01 Rainbow Medical Ltd. Electrical treatment of Parkinson's disease
EP3974021B1 (en) 2017-06-30 2023-06-14 ONWARD Medical N.V. A system for neuromodulation
US11033327B2 (en) * 2017-10-30 2021-06-15 St. Jude Medical, Cardiology Division, Inc. Electrophysiology catheter with modular electrode structure
JP2021507755A (en) * 2017-12-21 2021-02-25 ガルバニ バイオエレクトロニクス リミテッド Systems and methods configured to insert implants into the abdominal wall cavity
EP3765141A1 (en) 2018-03-14 2021-01-20 Rainbow Medical Ltd. Electrical substance clearance from the brain
EP3758793A4 (en) 2018-03-29 2021-12-08 Nevro Corp. Leads having sidewall openings, and associated systems and methods
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
EP3653260A1 (en) 2018-11-13 2020-05-20 GTX medical B.V. Sensor in clothing of limbs or footwear
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
US11648399B2 (en) * 2019-06-10 2023-05-16 Boston Scientific Neuromodulation Corporation Sensing reference electrode for percutaneous neuromodulation trials
US10881858B1 (en) 2019-09-18 2021-01-05 Rainbow Medical Ltd. Electrical substance clearance from the brain
DE19211698T1 (en) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system
US11298530B1 (en) 2021-05-03 2022-04-12 Discure Technologies Ltd. Synergistic therapies for intervertebral disc degeneration
US11344721B1 (en) 2021-08-16 2022-05-31 Rainbow Medical Ltd. Cartilage treatment
US11413455B1 (en) 2022-02-08 2022-08-16 Rainbow Medical Ltd. Electrical treatment of Alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391643B1 (en) * 1998-10-28 2002-05-21 Cygnus, Inc. Kit and method for quality control testing of an iontophoretic sampling system
US6625496B1 (en) * 2000-05-16 2003-09-23 Ela Medical S.A. Kit and method for installation of a probe implantable in the coronary network for stimulation of a cardiac cavity

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US538514A (en) 1895-04-30 haeselee
US661047A (en) 1900-08-29 1900-11-06 Elbert G Graves Cultivator and planter.
US4141365A (en) 1977-02-24 1979-02-27 The Johns Hopkins University Epidural lead electrode and insertion needle
US4285347A (en) 1979-07-25 1981-08-25 Cordis Corporation Stabilized directional neural electrode lead
US4519403A (en) 1983-04-29 1985-05-28 Medtronic, Inc. Balloon lead and inflator
US4608985A (en) 1984-10-11 1986-09-02 Case Western Reserve University Antidromic pulse generating wave form for collision blocking
US4658835A (en) 1985-07-25 1987-04-21 Cordis Corporation Neural stimulating lead with fixation canopy formation
US4739768B2 (en) 1986-06-02 1995-10-24 Target Therapeutics Inc Catheter for guide-wire tracking
US5365926A (en) 1986-11-14 1994-11-22 Desai Jawahar M Catheter for mapping and ablation and method therefor
US4813934A (en) 1987-08-07 1989-03-21 Target Therapeutics Valved catheter device and method
US4869255A (en) 1987-12-04 1989-09-26 Ad-Tech Medical Instrument Corp. Electrical connection device
SE8800019D0 (en) 1988-01-07 1988-01-07 Knut Olof Edhag FOR CARDIALLY DEFIBLATION USED INTRAVASCULES ELECTRO CABLE
US4884579A (en) 1988-04-18 1989-12-05 Target Therapeutics Catheter guide wire
US5010895A (en) 1989-08-03 1991-04-30 Empi, Inc. Expandable vaginal electrode
US5005587A (en) 1989-11-13 1991-04-09 Pacing Systems, Inc. Braid Electrode leads and catheters and methods for using the same
US5342410A (en) * 1990-10-05 1994-08-30 Eric Braverman Apparatus and method for increasing the amplitude of P300 waves in the human brain
US5170802A (en) 1991-01-07 1992-12-15 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5224491A (en) 1991-01-07 1993-07-06 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5107856A (en) * 1991-01-10 1992-04-28 Siemens-Pacesetter, Inc. Multiple lead suture sleeve
DK0791333T3 (en) 1991-12-12 2000-05-01 Target Therapeutics Inc Several extruder-carocclusion coil construction with interlocking coupling
US5234437A (en) 1991-12-12 1993-08-10 Target Therapeutics, Inc. Detachable pusher-vasoocclusion coil assembly with threaded coupling
US5261916A (en) 1991-12-12 1993-11-16 Target Therapeutics Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling
US5358514A (en) * 1991-12-18 1994-10-25 Alfred E. Mann Foundation For Scientific Research Implantable microdevice with self-attaching electrodes
SE9200803D0 (en) 1992-03-16 1992-03-16 Siemens Elema Ab defibrillation
US5239999A (en) 1992-03-27 1993-08-31 Cardiac Pathways Corporation Helical endocardial catheter probe
US5423877A (en) * 1992-05-04 1995-06-13 David C. Mackey Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion
US5782239A (en) 1992-06-30 1998-07-21 Cordis Webster, Inc. Unique electrode configurations for cardiovascular electrode catheter with built-in deflection method and central puller wire
EP0580928A1 (en) * 1992-07-31 1994-02-02 ARIES S.r.l. A spinal electrode catheter
US5306294A (en) 1992-08-05 1994-04-26 Ultrasonic Sensing And Monitoring Systems, Inc. Stent construction of rolled configuration
US5250071A (en) 1992-09-22 1993-10-05 Target Therapeutics, Inc. Detachable embolic coil assembly using interlocking clasps and method of use
US5350397A (en) 1992-11-13 1994-09-27 Target Therapeutics, Inc. Axially detachable embolic coil assembly
US5312415A (en) 1992-09-22 1994-05-17 Target Therapeutics, Inc. Assembly for placement of embolic coils using frictional placement
DE69323374T2 (en) * 1992-09-30 1999-06-10 Cardiac Pacemakers Inc Foldable cushion electrode for cardiac defibrillation with an area without conductors, which serves as a hinge
WO1994007564A2 (en) 1992-10-01 1994-04-14 Cardiac Pacemakers, Inc. Stent-type defibrillation electrode structures
US5263488A (en) 1992-10-05 1993-11-23 Nicolet Instrument Corporation Method and apparatus for localization of intracerebral sources of electrical activity
US5306272A (en) 1992-11-02 1994-04-26 Neuro Navigational Corporation Advancer for surgical instrument
SE9203734D0 (en) * 1992-12-11 1992-12-11 Siemens Elema Ab defibrillation
US5706809A (en) 1993-01-29 1998-01-13 Cardima, Inc. Method and system for using multiple intravascular sensing devices to detect electrical activity
US5792187A (en) 1993-02-22 1998-08-11 Angeion Corporation Neuro-stimulation to control pain during cardioversion defibrillation
WO1994021166A1 (en) 1993-03-16 1994-09-29 Ep Technologies, Inc. Multiple electrode support structures
US6572529B2 (en) 1993-06-17 2003-06-03 Wilk Patent Development Corporation Intrapericardial assist method
US5385528A (en) 1993-06-17 1995-01-31 Wilk; Peter J. Intrapericardial assist device and associated method
US5860974A (en) 1993-07-01 1999-01-19 Boston Scientific Corporation Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft
US5984909A (en) * 1993-08-13 1999-11-16 Daig Corporation Coronary sinus catheter
US5417719A (en) 1993-08-25 1995-05-23 Medtronic, Inc. Method of using a spinal cord stimulation lead
US5464446A (en) 1993-10-12 1995-11-07 Medtronic, Inc. Brain lead anchoring system
US5582609A (en) 1993-10-14 1996-12-10 Ep Technologies, Inc. Systems and methods for forming large lesions in body tissue using curvilinear electrode elements
US5989280A (en) * 1993-10-22 1999-11-23 Scimed Lifesystems, Inc Stent delivery apparatus and method
EP0861676B1 (en) 1993-11-10 2003-10-01 Medtronic Cardiorhythm Electrode array catheter
US5501703A (en) * 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US5462545A (en) 1994-01-31 1995-10-31 New England Medical Center Hospitals, Inc. Catheter electrodes
US5443492A (en) * 1994-02-02 1995-08-22 Medtronic, Inc. Medical electrical lead and introducer system for implantable pulse generator
US5517989A (en) 1994-04-01 1996-05-21 Cardiometrics, Inc. Guidewire assembly
US5693085A (en) 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
US5543864A (en) 1994-10-11 1996-08-06 Hudson Optical Corporation Method and kit for attaching side shields to eyeglass temples
US5603731A (en) 1994-11-21 1997-02-18 Whitney; Douglass G. Method and apparatus for thwarting thrombosis
US5814062A (en) 1994-12-22 1998-09-29 Target Therapeutics, Inc. Implant delivery assembly with expandable coupling/decoupling mechanism
IL116561A0 (en) * 1994-12-30 1996-03-31 Target Therapeutics Inc Severable joint for detachable devices placed within the body
US5707354A (en) 1995-04-17 1998-01-13 Cardiovascular Imaging Systems, Inc. Compliant catheter lumen and methods
US5611345A (en) * 1995-04-24 1997-03-18 Hibbeln; John F. Medical instrument with improved ultrasonic visibility
US5534007A (en) 1995-05-18 1996-07-09 Scimed Life Systems, Inc. Stent deployment catheter with collapsible sheath
US5702438A (en) 1995-06-08 1997-12-30 Avitall; Boaz Expandable recording and ablation catheter system
US6480743B1 (en) * 2000-04-05 2002-11-12 Neuropace, Inc. System and method for adaptive brain stimulation
US5755750A (en) * 1995-11-13 1998-05-26 University Of Florida Method and apparatus for selectively inhibiting activity in nerve fibers
NL1001890C2 (en) 1995-12-13 1997-06-17 Cordis Europ Catheter with plate-shaped electrode array.
US5846238A (en) 1996-01-19 1998-12-08 Ep Technologies, Inc. Expandable-collapsible electrode structures with distal end steering or manipulation
US5871483A (en) 1996-01-19 1999-02-16 Ep Technologies, Inc. Folding electrode structures
US5891136A (en) 1996-01-19 1999-04-06 Ep Technologies, Inc. Expandable-collapsible mesh electrode structures
US6066163A (en) 1996-02-02 2000-05-23 John; Michael Sasha Adaptive brain stimulation method and system
US6463328B1 (en) * 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
US6152899A (en) 1996-03-05 2000-11-28 Vnus Medical Technologies, Inc. Expandable catheter having improved electrode design, and method for applying energy
US5713922A (en) 1996-04-25 1998-02-03 Medtronic, Inc. Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain
US5925070A (en) 1996-04-04 1999-07-20 Medtronic, Inc. Techniques for adjusting the locus of excitation of electrically excitable tissue
US5716377A (en) 1996-04-25 1998-02-10 Medtronic, Inc. Method of treating movement disorders by brain stimulation
US5683422A (en) 1996-04-25 1997-11-04 Medtronic, Inc. Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation
US6006134A (en) 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US5782798A (en) * 1996-06-26 1998-07-21 Medtronic, Inc. Techniques for treating eating disorders by brain stimulation and drug infusion
US5800474A (en) * 1996-11-01 1998-09-01 Medtronic, Inc. Method of controlling epilepsy by brain stimulation
US5752979A (en) 1996-11-01 1998-05-19 Medtronic, Inc. Method of controlling epilepsy by brain stimulation
US6071279A (en) 1996-12-19 2000-06-06 Ep Technologies, Inc. Branched structures for supporting multiple electrode elements
WO1998029030A1 (en) 1997-01-03 1998-07-09 Biosense Inc. Pressure-sensing stent
EP0855196A1 (en) 1997-01-28 1998-07-29 Sulzer Osypka GmbH Defibrillation electrode
US5938596A (en) 1997-03-17 1999-08-17 Medtronic, Inc. Medical electrical lead
US6015387A (en) 1997-03-20 2000-01-18 Medivas, Llc Implantation devices for monitoring and regulating blood flow
US5954761A (en) 1997-03-25 1999-09-21 Intermedics Inc. Implantable endocardial lead assembly having a stent
US5948007A (en) 1997-04-30 1999-09-07 Medtronic, Inc. Dual channel implantation neurostimulation techniques
US6128537A (en) * 1997-05-01 2000-10-03 Medtronic, Inc Techniques for treating anxiety by brain stimulation and drug infusion
US6119044A (en) 1997-06-02 2000-09-12 Advanced Bionics Corporation Cochlear electrode array with positioning stylet
US6547788B1 (en) * 1997-07-08 2003-04-15 Atrionx, Inc. Medical device with sensor cooperating with expandable member
US5902236A (en) 1997-09-03 1999-05-11 Pmt Corporation Tissue electrode for recording and stimulation
US5967986A (en) 1997-11-25 1999-10-19 Vascusense, Inc. Endoluminal implant with fluid flow sensing capability
US6231516B1 (en) 1997-10-14 2001-05-15 Vacusense, Inc. Endoluminal implant with therapeutic and diagnostic capability
US6074407A (en) 1997-10-14 2000-06-13 Target Therapeutics, Inc. Delivery catheter for occlusive implants
US6647296B2 (en) * 1997-10-27 2003-11-11 Neuropace, Inc. Implantable apparatus for treating neurological disorders
US6016449A (en) 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6014589A (en) 1997-11-12 2000-01-11 Vnus Medical Technologies, Inc. Catheter having expandable electrodes and adjustable stent
US5931862A (en) * 1997-12-22 1999-08-03 Pacesetter, Inc. Medical lead and method of making and using with sodium sulfosuccinic ester
US20020188207A1 (en) 1998-01-08 2002-12-12 Jacob Richter Anchor for sensor implanted in a bodily lumen
US6074507A (en) 1998-01-09 2000-06-13 Corrugating Roll Corporation Corrugating roll with improved flute profile
US6415187B1 (en) * 1998-02-10 2002-07-02 Advanced Bionics Corporation Implantable, expandable, multicontact electrodes and insertion needle for use therewith
US6205361B1 (en) 1998-02-10 2001-03-20 Advanced Bionics Corporation Implantable expandable multicontact electrodes
US6522932B1 (en) * 1998-02-10 2003-02-18 Advanced Bionics Corporation Implantable, expandable, multicontact electrodes and tools for use therewith
US5902331A (en) * 1998-03-10 1999-05-11 Medtronic, Inc. Arrangement for implanting an endocardial cardiac lead
US6319241B1 (en) 1998-04-30 2001-11-20 Medtronic, Inc. Techniques for positioning therapy delivery elements within a spinal cord or a brain
US6161047A (en) 1998-04-30 2000-12-12 Medtronic Inc. Apparatus and method for expanding a stimulation lead body in situ
WO1999056818A1 (en) 1998-04-30 1999-11-11 Medtronic, Inc. Multiple electrode lead body for spinal cord stimulation
US6018682A (en) * 1998-04-30 2000-01-25 Medtronic, Inc. Implantable seizure warning system
US6421566B1 (en) * 1998-04-30 2002-07-16 Medtronic, Inc. Selective dorsal column stimulation in SCS, using conditioning pulses
US5938689A (en) 1998-05-01 1999-08-17 Neuropace, Inc. Electrode configuration for a brain neuropacemaker
US6006124A (en) 1998-05-01 1999-12-21 Neuropace, Inc. Means and method for the placement of brain electrodes
US6179858B1 (en) 1998-05-12 2001-01-30 Massachusetts Institute Of Technology Stent expansion and apposition sensing
US6091980A (en) 1998-05-12 2000-07-18 Massachusetts Institute Of Technology Stent slip sensing system and method
US6266568B1 (en) 1998-06-02 2001-07-24 Advanced Bionics Corporation Inflatable cochlear electrode array and method of making same
DE19826624A1 (en) * 1998-06-18 1999-12-23 Merck Patent Gmbh Pigment preparation
US6094596A (en) 1998-06-19 2000-07-25 Angeron Corporation Transvenous defibrillation lead system for use in middle cardiac vein
US6027456A (en) * 1998-07-10 2000-02-22 Advanced Neuromodulation Systems, Inc. Apparatus and method for positioning spinal cord stimulation leads
US6002964A (en) * 1998-07-15 1999-12-14 Feler; Claudio A. Epidural nerve root stimulation
US6370427B1 (en) 1998-07-23 2002-04-09 Intermedics, Inc. Method and apparatus for dual chamber bi-ventricular pacing and defibrillation
US6319251B1 (en) 1998-09-24 2001-11-20 Hosheng Tu Medical device and methods for treating intravascular restenosis
US6036689A (en) 1998-09-24 2000-03-14 Tu; Lily Chen Ablation device for treating atherosclerotic tissues
US6253109B1 (en) * 1998-11-05 2001-06-26 Medtronic Inc. System for optimized brain stimulation
IT1305062B1 (en) 1998-12-23 2001-04-10 Leonardo Cammilli SINGLE INTRODUCTION CATHETER FOR MULTISITE STIMULATION OF THE FOUR CARDIAC CHAMBERS FOR TREATMENT OF PATHOLOGIES SUCH AS
US6393325B1 (en) * 1999-01-07 2002-05-21 Advanced Bionics Corporation Directional programming for implantable electrode arrays
US6192279B1 (en) * 1999-02-23 2001-02-20 Medtronic, Inc. Non-invasively maneuverable lead system
US6161029A (en) 1999-03-08 2000-12-12 Medtronic, Inc. Apparatus and method for fixing electrodes in a blood vessel
DE19912635A1 (en) * 1999-03-20 2000-09-21 Biotronik Mess & Therapieg Dilatable cardiac electrode arrangement for implantation, particularly in the coronary sinus of the heart
US6136021A (en) 1999-03-23 2000-10-24 Cardiac Pacemakers, Inc. Expandable electrode for coronary venous leads
US6170488B1 (en) 1999-03-24 2001-01-09 The B. F. Goodrich Company Acoustic-based remotely interrogated diagnostic implant device and system
US6361528B1 (en) 1999-04-05 2002-03-26 Acist Medical Systems, Inc. Dynamically compliant catheter
US6330477B1 (en) 1999-04-12 2001-12-11 Medtronic, Inc. Ventricular synchronized atrial pacing mode of implantable cardioverter/defibrillator
US6317615B1 (en) * 1999-04-19 2001-11-13 Cardiac Pacemakers, Inc. Method and system for reducing arterial restenosis in the presence of an intravascular stent
US6216045B1 (en) * 1999-04-26 2001-04-10 Advanced Neuromodulation Systems, Inc. Implantable lead and method of manufacture
US20010025192A1 (en) 1999-04-29 2001-09-27 Medtronic, Inc. Single and multi-polar implantable lead for sacral nerve electrical stimulation
US6353762B1 (en) 1999-04-30 2002-03-05 Medtronic, Inc. Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve
US6249707B1 (en) 1999-04-30 2001-06-19 Medtronic, Inc. Apparatus and method for percutaneous implant of a paddle style lead
US6192280B1 (en) * 1999-06-02 2001-02-20 Medtronic, Inc. Guidewire placed implantable lead with tip seal
US6539263B1 (en) * 1999-06-11 2003-03-25 Cornell Research Foundation, Inc. Feedback mechanism for deep brain stimulation
AU6953300A (en) 1999-07-07 2001-01-22 Cardiac Pacemakers, Inc. Endocardial electrode assembly having conductive fixation features
US6516227B1 (en) * 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
EP1106202A3 (en) 1999-11-30 2004-03-31 BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin Electrode for intravascular stimulation, cardioversion and /or defibrillation
TW483768B (en) * 1999-12-07 2002-04-21 George Mason Universityi Adaptive electric field modulation of neural systems
US6662055B1 (en) * 1999-12-17 2003-12-09 Impulse Dynamics Nv Multi-electrode intravascular lead
US6584358B2 (en) * 2000-01-07 2003-06-24 Biowave Corporation Electro therapy method and apparatus
US6587733B1 (en) * 2000-02-08 2003-07-01 Medtronic, Inc. Percutaneous surgical lead body with directed stimulation
US6418344B1 (en) 2000-02-24 2002-07-09 Electrocore Techniques, Llc Method of treating psychiatric disorders by electrical stimulation within the orbitofrontal cerebral cortex
US6430442B1 (en) * 2000-02-29 2002-08-06 Medtronic, Inc. Split contact with super elastic retaining ring for implantable medical device
US6466822B1 (en) * 2000-04-05 2002-10-15 Neuropace, Inc. Multimodal neurostimulator and process of using it
ATE432664T1 (en) 2000-05-03 2009-06-15 Bard Inc C R DEVICE FOR MULTI-DIMENSIONAL DISPLAY AND ABLATION IN ELECTROPHYSIOLOGICAL PROCEDURES
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US6408214B1 (en) 2000-07-11 2002-06-18 Medtronic, Inc. Deflectable tip catheter for CS pacing
US6895283B2 (en) 2000-08-10 2005-05-17 Advanced Neuromodulation Systems, Inc. Stimulation/sensing lead adapted for percutaneous insertion
US6510347B2 (en) * 2000-08-17 2003-01-21 William N. Borkan Spinal cord stimulation leads
US6591138B1 (en) * 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US6529774B1 (en) * 2000-11-09 2003-03-04 Neuropace, Inc. Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation
US6369325B1 (en) * 2000-11-20 2002-04-09 Chung-Ching Wu Switch box for a ceiling fan
US6697676B2 (en) 2000-12-21 2004-02-24 Medtronic, Inc. Medical electrical lead having an expandable electrode assembly
US6445953B1 (en) * 2001-01-16 2002-09-03 Kenergy, Inc. Wireless cardiac pacing system with vascular electrode-stents
US6600954B2 (en) * 2001-01-25 2003-07-29 Biocontrol Medical Bcm Ltd. Method and apparatus for selective control of nerve fibers
US6597953B2 (en) * 2001-02-20 2003-07-22 Neuropace, Inc. Furcated sensing and stimulation lead
US6671544B2 (en) * 2001-06-28 2003-12-30 Medtronic, Inc. Low impedance implantable extension for a neurological electrical stimulator
US6606521B2 (en) * 2001-07-09 2003-08-12 Neuropace, Inc. Implantable medical lead
US7455666B2 (en) 2001-07-13 2008-11-25 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
US6600956B2 (en) * 2001-08-21 2003-07-29 Cyberonics, Inc. Circumneural electrode assembly
US7072719B2 (en) * 2001-09-20 2006-07-04 Medtronic, Inc. Implantable percutaneous stimulation lead with interlocking elements
US6909918B2 (en) * 2001-10-10 2005-06-21 Medtronic, Inc. Implantable percutaneous stimulation lead with lead carrier
DE10153842A1 (en) * 2001-10-24 2003-05-08 Biotronik Mess & Therapieg electrode assembly
US6835311B2 (en) 2002-01-31 2004-12-28 Koslow Technologies Corporation Microporous filter media, filtration systems containing same, and methods of making and using
JP2005515819A (en) * 2002-02-01 2005-06-02 ザ クリーブランド クリニック ファウンデイション A transmission device that stimulates the sympathetic nerve chain
US7191015B2 (en) 2002-04-11 2007-03-13 Medtronic Vascular, Inc. Devices and methods for transluminal or transthoracic interstitial electrode placement
US20030199962A1 (en) 2002-04-22 2003-10-23 Chester Struble Anti-slip leads for placement within tissue
US7697995B2 (en) 2002-04-25 2010-04-13 Medtronic, Inc. Surgical lead paddle
US7283861B2 (en) 2002-04-30 2007-10-16 Alexander Bystritsky Methods for modifying electrical currents in neuronal circuits
US6988007B1 (en) * 2002-08-13 2006-01-17 Pacesetter, Inc. Single pass telescoping cardiac lead for the left heart
US7047084B2 (en) 2002-11-20 2006-05-16 Advanced Neuromodulation Systems, Inc. Apparatus for directionally stimulating nerve tissue
AU2004204674A1 (en) 2003-01-03 2004-07-29 Advanced Neuromodulation Systems, Inc. System and method for stimulation of a person's brain stem
WO2004073782A1 (en) 2003-02-19 2004-09-02 Taewoong Medical Co., Ltd Stent for high frequency thermotherapy
US6999820B2 (en) 2003-05-29 2006-02-14 Advanced Neuromodulation Systems, Inc. Winged electrode body for spinal cord stimulation
US20050004639A1 (en) * 2003-07-03 2005-01-06 Advanced Neuromodulation Systems, Inc. Medical lead with resorbable material
US20050137646A1 (en) 2003-12-22 2005-06-23 Scimed Life Systems, Inc. Method of intravascularly delivering stimulation leads into brain
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US20050203600A1 (en) 2004-03-12 2005-09-15 Scimed Life Systems, Inc. Collapsible/expandable tubular electrode leads
US7177702B2 (en) 2004-03-12 2007-02-13 Scimed Life Systems, Inc. Collapsible/expandable electrode leads
US7590454B2 (en) 2004-03-12 2009-09-15 Boston Scientific Neuromodulation Corporation Modular stimulation lead network
US8412348B2 (en) 2004-05-06 2013-04-02 Boston Scientific Neuromodulation Corporation Intravascular self-anchoring integrated tubular electrode body
US7937160B2 (en) 2004-12-10 2011-05-03 Boston Scientific Neuromodulation Corporation Methods for delivering cortical electrode leads into patient's head

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391643B1 (en) * 1998-10-28 2002-05-21 Cygnus, Inc. Kit and method for quality control testing of an iontophoretic sampling system
US6625496B1 (en) * 2000-05-16 2003-09-23 Ela Medical S.A. Kit and method for installation of a probe implantable in the coronary network for stimulation of a cardiac cavity

Also Published As

Publication number Publication date
EP1722846A1 (en) 2006-11-22
JP4635045B2 (en) 2011-02-16
US7590454B2 (en) 2009-09-15
US20090319012A1 (en) 2009-12-24
ES2363086T3 (en) 2011-07-20
EP1722846B1 (en) 2011-05-25
JP2007528776A (en) 2007-10-18
US20050203599A1 (en) 2005-09-15
ATE510580T1 (en) 2011-06-15
US8185208B2 (en) 2012-05-22
CA2557743A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
EP1722846B1 (en) Modular stimulation lead network
US7177702B2 (en) Collapsible/expandable electrode leads
US8019441B2 (en) Collapsible/expandable tubular electrode leads
US8224459B1 (en) Insertion tool for paddle-style electrode
US8983625B2 (en) Systems and methods for electrically stimulating patient tissue on or around one or more bony structures
US7392093B2 (en) Electrical stimulation system including a device for partially shielding electrical energy emitted from one or more electrical stimulation leads implanted in a human's body
EP2318090B1 (en) Implantable neural stimulation electrode assemblies
US20030078633A1 (en) Methods and implantable apparatus for electrical therapy
US8805544B2 (en) Insertion tool for paddle-style electrode
US20170333702A1 (en) Systems and method for anchoring a lead for neurostimulation of a target anatomy
US20050004639A1 (en) Medical lead with resorbable material
WO2005082453A1 (en) System and method for neurological stimulation of peripheral nerves to treat low back pain
US20150005783A1 (en) Assembly kit for creating paddle-style lead from one or several percutaneous leads and method of lead implantation
US10376689B2 (en) Leads for extraforaminal stimulation of dorsal roots and dorsal root ganglia and related methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2557743

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007502876

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005724681

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005724681

Country of ref document: EP